

# clinician's brief®

A Peer-Reviewed Journal | [cliniciansbrief.com](http://cliniciansbrief.com)

## TOP 5 SIGNS OF PATIENT STRESS & EXCITEMENT ON CLINICAL PATHOLOGY

### IN THIS ISSUE

Diagnosing Acute Lameness in a Pointer

Step-by-Step Digit Amputation in Dogs

The Case: Eyelid Mass with Conjunctival & Periocular Swelling in a Cat

Differential Diagnoses for Splenomegaly in Dogs

Decision Tree: Elevated Total Thyroxine in Cats

Decision Tree: Low Total Thyroxine in Dogs



Volume 20 Number 3



**clinician's brief®**  
THE OFFICIAL CLINICAL PRACTICE JOURNAL OF THE WSAVA



CANADIAN VETERINARY  
MEDICAL ASSOCIATION  
L'ASSOCIATION CANADIENNE  
DES MÉDECINS VÉTÉRINAIRES

# clinician's brief®

A Peer-Reviewed Journal | [cliniciansbrief.com](http://cliniciansbrief.com)

## ANTECH®

BETTER DIAGNOSTICS. BETTER MEDICINE.™

**Healthy pets. Happy pet parents.  
High-performance practice.**



# ANTECH<sup>®</sup>

BETTER DIAGNOSTICS. BETTER MEDICINE.™

## Get more reliable, efficient, and affordable diagnostics with Antech.

Diagnostics are essential to your practice. Partner with Antech and reclaim valuable time to focus on your patients and their pet parents—and yourself.

### **Reliable**

Trusted by thousands of veterinarians, Antech delivers fast and accurate results.

### **Efficient**

Optimized, time-saving workflows for wellness testing, routine diagnostics, and specialty tests.

### **Affordable**

We help you minimize operational costs and deliver optimal quality.

---

**Experience Antech's flexible, can-do spirit.**

**CALL 1-800-872-1001 VISIT [q-r.to/antech-briefc-0422](https://q-r.to/antech-briefc-0422)**

© 2022 Antech Diagnostics, Inc. All rights reserved. Antech and the Antech logo are the registered trademarks of Antech Diagnostics, Inc. or its affiliates. 032322



# A HARDY SKIN BARRIER: the best defense against allergens



# DERMAQUIN<sup>®</sup>


## SKIN SUPPORT SUPPLEMENT

with hardy kiwi

Available in SOFT CHEWS for small/medium and large dogs  
To learn more, visit [DERMAQUIN.COM](http://DERMAQUIN.COM)

010.1446.00  
**nutramax**  
LABORATORIES  
VETERINARY SCIENCES, INC.

## TEAM



EDITOR IN CHIEF  
**J. SCOTT WEESE**  
DVM, DVSc, DACVIM,  
FCAHS  
dr.weese@briefmedia.com  
Professor  
Ontario Veterinary College  
Ontario, Canada



CHIEF SCIENTIFIC  
OFFICER  
**INDU MANI**  
DVM, DSc  
dr.indu@briefmedia.com



VETERINARY OFFICER,  
CLINICAL RESOURCES  
**JENNIFER L. SCHORI**  
VMD, MS  
dr.jen@briefmedia.com



MANAGING EDITOR,  
*CLINICIAN'S BRIEF*  
**SARAH TYLER**  
sarah@briefmedia.com

### CEO/FOUNDER

ELIZABETH GREEN  
elizabeth@briefmedia.com

### ADVERTISING

CHRISTIE BARDO  
christie@briefmedia.com

SHELLEY HEROD  
shelley@briefmedia.com

NAOMI MURRAY, DVM  
dr.naomi@briefmedia.com

JOANNA LUNDBERG  
joanna@briefmedia.com

MELISSA ROBERTS  
melissa@briefmedia.com

AMANDA ANDERSON  
aanderson@briefmedia.com

DRAKE BOONE  
drake@briefmedia.com

### MARKETING SERVICES

ROSIE SEIBERT  
rosie@briefmedia.com

MEGAN WHITWORTH-SWANSON  
megan@briefmedia.com

DRUE A. GINDLER  
drue@briefmedia.com

SARAH PATE  
sarahpate@briefmedia.com

SHELBI WHITE  
shelbi@briefmedia.com

ELIZABETH MOLLESON, DVM  
dr.beth@briefmedia.com

TAYLOR AUSTIN  
taylor.austin@briefmedia.com

EXECUTIVE EDITOR  
**MICHELLE N. MUNKRES**  
MA  
michelle@briefmedia.com

ASSISTANT EDITOR  
**MARY HALLER**  
mary@briefmedia.com

EDITORIAL ASSOCIATE  
**CALLIE HUSTON**  
callie@briefmedia.com

EDITORIAL ASSISTANT  
**MAYA TAYLOR**  
maya@briefmedia.com

EDITOR AT LARGE  
**ANTOINETTE PASSARETTI**  
toni@briefmedia.com

MANAGING EDITOR,  
AUDIENCE GROWTH & ENGAGEMENT  
**EMILY FAISON**  
MA  
emily@briefmedia.com

ASSISTANT EDITOR, AUDIENCE  
GROWTH & ENGAGEMENT  
**TAYLOR TOWNSLEY**  
taylor@briefmedia.com

DIGITAL CONTENT COORDINATOR  
**ALEXIS USSERY**  
alexis@briefmedia.com

DIRECTOR, DIGITAL CONTENT  
& AUDIENCE GROWTH  
**LANCE WILLIAMS**  
lance@briefmedia.com

INTERACTIVE MEDICAL EDITOR  
**ALYSSA WATSON**  
DVM  
dr.alyssa@briefmedia.com

DESIGN & PRODUCTION  
**JEANNE MISTRETТА**  
Mistretta Design Group, LLC  
jeanne@mistrettadesigngroup.com

CREATIVE DIRECTOR  
**AARON MAYS**  
aaron@briefmedia.com

CHIEF MEDICAL OFFICER  
**AMY MOHL**  
DVM  
dr.amy@briefmedia.com

VETERINARY OFFICER, AUDIENCE  
GROWTH & ENGAGEMENT  
**PEGGY BURRIS**  
DVM  
dr.peggy@briefmedia.com

**Providing  
small animal  
practitioners and  
their teams with  
practical, relevant  
information on  
the latest topics  
in veterinary  
medicine**

### TO SUBSCRIBE OR FOR SUBSCRIPTION INQUIRIES: [CLINICIANSBRIEF.COM/SUBSCRIBE](http://CLINICIANSBRIEF.COM/SUBSCRIBE) OR 1-847-763-4909

Domestic subscription rate: \$65.00 per year. Single copy: \$8.00. Payments by check must be in US funds on a US branch of a US bank only; credit cards also accepted.

Copyright © 2022 Brief Media, an Educational Concepts company. All rights reserved.

Reproduction in whole or in part without expressed written permission is prohibited.

POSTMASTER: Send address changes to Brief Media, PO Box 1084, Skokie, IL 1084 60076-9969. Canada Post publications mail agreement #40932038: Return undeliverable Canadian mailings to Circulation Dept; 7496 Bath Rd, Unit #2; Mississauga, ON L4T 1L2. Periodicals postage paid at Tulsa, OK, and at additional mailing offices.

**BRIEF MEDIA:** 110 S Hartford Ave, Suite 2507, Tulsa, OK 74120  
T 918-749-0118 | F 918-749-1987 | [briefmedia.com](http://briefmedia.com) | [info@briefmedia.com](mailto:info@briefmedia.com)

*Clinician's Brief* (ISSN 1542-4014) is published 8 times annually by Brief Media, an Educational Concepts company, 110 S Hartford Ave, Suite 2507, Tulsa, OK 74120.







# OrthoLine™ Fracture Management System

*Including 70 Plate Options for Patients of Every Size*

## First Small Animal Fracture Management System with the Designs You Asked for:

- High screw density where it's needed
- Slide and compression holes
- Low plate contact and low profile
- Strong bridging design
- Variable, locking, and cortical screws\*
- Extensive size range of headless compression screws



\*The 3.5 mm size is stainless steel and does not include a variable angle screw option.

†All weight ranges are suggestions based on the ultimate load of the product and/or on our veterinary consultant's recommendation. It is up to the veterinarian to determine the proper product, application, technique, and weight range for the selected product.

# OUR AUTHORS

**JUDITH BERTRAN**, DVM, MS, DACVS (SA), is an assistant professor of surgical oncology at University of Florida. Dr. Bertran earned her DVM from Autonomous University of Barcelona in Spain. She also completed an internship in small animal medicine and surgery at Washington State University, an internship in small animal surgery at Fitzpatrick Referrals in Godalming, England, and a residency in small animal surgery and a surgical oncology fellowship at The Ohio State University, where she also earned her MS. Her research interests are in metastatic cancer to the lymph nodes, lymph node mapping, and molecular profiles of metastatic lymph nodes.

**PROCEDURES PRO PAGE 65**

**SARAH BOSCH**, DVM, is pursuing a clinical pathology residency at University of Florida. She earned her DVM from Cummings School of Veterinary Medicine at Tufts University and completed a diagnostic medicine internship at Kansas State University.

**CASE IN POINT PAGE 55**

**KRISTYN D. BROADDUS**, DVM, MS, DACVS, is a small animal surgeon and owner of Veterinary Specialists of Hanover in Mechanicsville, Virginia. Dr. Broaddus earned her DVM from Michigan State University. She completed a small animal rotating internship and small animal surgery residency and earned her MS at Auburn University. Her interests are in soft tissue surgery, orthopedics, and teaching and speaking at veterinary continuing education events.

**HISTORY & PHYSICAL EXAMINATION PAGE 12**

**ELIJAH ERNST**, DVM, is a resident in small animal internal medicine at North Carolina State University, where he also completed a rotating medicine and surgery internship. He earned his DVM from The Ohio State University.

**DIFFERENTIAL DIAGNOSIS PAGE 61**

**KARYN HARRELL**, DVM, DACVIM (SAIM), is an assistant professor at North Carolina State University, where she also serves as intern director of small animal rotating internships and established the radioactive iodine clinic. Her clinical interests include hematology and immunology, especially immune-mediated hemolytic anemia and idiopathic thrombocytopenia, and teaching clinical medicine.

**DIFFERENTIAL DIAGNOSIS PAGE 61**

**HEATHER KVITKO-WHITE**, DVM, DACVIM (SAIM), is a small animal internal medicine specialist, founder and president of KW Veterinary Consulting in Kansas City, Missouri, and a national speaker who promotes a creative and common-sense approach to caring for patients without sacrificing quality. She earned her DVM from The Ohio State University, completed a small animal rotating internship at Purdue University, and completed an internal medicine residency at Texas A&M University. Her interests are in teaching pragmatic veterinary medicine, mentoring veterinary students and house officers, and developing continuing education content at all industry levels.

**DIAGNOSTIC/MANAGEMENT TREE PAGE 18**

**PATTY LATHAN**, VMD, MS, DACVIM (SAIM), is an associate professor of small animal internal medicine at Mississippi State University, where she also completed an internship. Dr. Lathan completed a small animal internal medicine residency at Purdue University. Her clinical interests are in adrenal function testing, diabetes mellitus, and stress hyperglycemia.

**DIAGNOSTIC/MANAGEMENT TREE PAGE 20**

**KA YUNG LEE**, DVM, is a small animal rotating intern at Tuskegee University. Dr. Lee earned her DVM at Kyungpook National University in Daegu, South Korea, and participated in VSTEP at Ontario Veterinary College in Guelph, Ontario, Canada. Her clinical interests are in soft tissue surgery, surgical oncology, and international veterinary medicine.

**PROCEDURES PRO PAGE 65**

Continues on page 5



 **nocita™**  
(bupivacaine liposome injectable suspension)

# SEE THE DIFFERENCE

Pain and dysphoria don't have to be part of the post-op experience.\*

Controls Pain to Help Post-Op Return to Function	Single-Dose Administration	FDA-Approved	
Long-Acting Local Anesthetic	UP TO 72-HOUR ANALGESIA		
<p><b>Canine CCL** and feline onychectomy patients can recover comfortably even after going home.</b></p> <p style="text-align: right;"><b>Recovery care begins with Nocita™</b></p>			

## Indications

For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.

## Important Safety Information

NOCITA is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. Please see accompanying brief summary for product safety information.

\*In a field trial, Nocita reduced the need for post-op rescue pain treatment with opioids

\*\*Cranial cruciate ligament

Nocita, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

©2021 Elanco or its affiliates. PM-US-21-1708

See page 5 for product information summary.



# NOCITA®

(bupivacaine liposome injectable suspension)

**13.3 mg/mL**

**For local infiltration injection in dogs only**

**For use as a peripheral nerve block in cats only**

**Local anesthetic**

**Single use vial**

**Caution:**

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**Before using this product, please consult the Product Insert, a summary of which follows:**

**DOG Indication:**

For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial crucia ligament surgery in dogs.

**CAT Indication:**

For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.

**DOG Dosage and Administration:**

NOCITA is for single dose administration only. A dose of 5.3 mg/kg (0.4 mL/kg) is administered by infiltration injection into the tissue layers at the time of incisional closure for dogs. A single dose administered during surgical closure may provide up to 72 hours of pain control.

**CAT Dosage and Administration:**

NOCITA is for administration only once prior to surgery. Administer 5.3 mg/kg per forelimb (0.4 mL/kg per forelimb, for a total dose of 10.6 mg/kg/cat) as a 4-point nerve block prior to onychectomy. Administration prior to surgery may provide up to 72 hours of pain control.

**Contraindications:**

Do not administer by intravenous or intra-arterial injection. If accidental intravascular administration occurs, monitor for cardiovascular (dysrhythmias, hypotension, hypertension) and neurologic (tremors, ataxia, seizures) adverse reactions. Do not use for intra-articular injection. In humans, local anesthetics administered into a joint may cause chondrolysis.

**Warnings:**

Not for use in humans. Keep out of reach of children. NOCITA is an amide local anesthetic. In case of accidental injection or accidental topical exposure, contact a physician and seek medical attention immediately. Wear gloves when handling vials to prevent accidental topical exposure.

**Precautions:**

Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. A safe interval from time of bupivacaine HCl, lidocaine or other amide local anesthetic administration to time of NOCITA administration has not been determined. The toxic effects of these drugs are additive and their administration should be used with caution including monitoring for neurologic and cardiovascular effects related to toxicity.

The safe use of NOCITA in dogs or cats with cardiac disease has not been evaluated.

The safe use of NOCITA in dogs or cats with hepatic or renal impairment has not been evaluated.

NOCITA is metabolized by the liver and excreted by the kidneys.

The ability of NOCITA to achieve effective anesthesia has not been studied. Therefore, NOCITA is not indicated for pre-incisional or pre-procedural loco-regional anesthetic techniques that require deep and complete sensory block in the area of administration.

The safe use of NOCITA in dogs for surgical procedures other than cranial cruciate ligament surgery has not been evaluated.

The safe use of NOCITA in cats for surgical procedures other than onychectomy has not been evaluated.

The safe use of NOCITA has not been evaluated in dogs or cats younger than 5 months old.

The safe use of NOCITA has not been evaluated in dogs or cats that are pregnant, lactating or intended for breeding.

**DOG Adverse Reactions:**

Field safety was evaluated in 123 NOCITA treated dogs. The most common adverse reactions were discharge from incision (3.3%), incisional inflammation (2.4%), and vomiting (2.4%).

**CAT Adverse Reactions:**

Field safety was evaluated in 120 NOCITA treated cats. The most common adverse reactions were elevated temperature (6.7%), surgical site infection (3.3%), and chewing/licking of the surgical site (2.5%).

**Storage Conditions:**

Unopened vials should be stored refrigerated between 36° F to 46° F (2° C to 8° C) NOCITA may be held at a controlled room temperature of 68° F to 77° F (20° C to 25° C) for up to 30 days in sealed, intact (unopened) vials. Do not re-refrigerate. **Do Not Freeze.**

**How Supplied:**

13.3 mg/mL bupivacaine liposome injectable suspension in 10 mL or 20 mL single use vial. 10 mL supplied in 4-vial carton. 20 mL supplied in a single vial carton and 4-vial carton.

NADA 141-461, Approved by the FDA

US Patent: 8,182,835; 8,834,921; 9,205,052



Manufactured for: Aratana Therapeutics, Inc., Leawood, KS 66211

Additional Information is available at [www.aratana.com](http://www.aratana.com) or by calling Aratana Therapeutics at 1-844-272-8262. NOCITA is a registered trademark of Aratana Therapeutics, Inc. © Aratana Therapeutics, Inc.

NOC-0088-2

August 2018

**JESSICA MEEKINS**, DVM, MS, DACVO, is an associate professor of ophthalmology at Kansas State University. Dr. Meekins earned her DVM from The Ohio State University, completed a rotating internship at a private specialty hospital in Albuquerque, New Mexico, and was accepted into the ophthalmology residency training program at Purdue University. Her clinical and research interests are in management of viral surface ocular diseases in cats.

**CASE IN POINT PAGE 55**

**SUSAN NELSON**, DVM, is a clinical professor at Kansas State University, where she also earned her DVM. Dr. Nelson also works in conjunction with mental health therapists in the instruction of communication skills. Her interests are in wellness, preventive medicine, and palliative care options for patients unable to receive advanced treatment.

**CASE IN POINT PAGE 55**

**LISA M. POHLMAN**, DVM, MS, DACVP, is an associate professor of clinical pathology at Kansas State University. She earned her DVM from University of Guelph and her MS from Auburn University, where she also completed a residency. Dr. Pohlman serves as the president and medical director of the Riley County Humane Society in Manhattan, Kansas, and is an active teacher and mentor of veterinary interns, residents, and graduate students. Her research interests include improvement of clinical pathology laboratory methods and identification and characterization of disease in domestic species.

**CASE IN POINT PAGE 55**

**R. DARREN WOOD**, DVM, DVSc, DACVP (Clinical Pathology), is an associate professor of clinical pathology at University of Guelph in Guelph, Ontario, Canada, where he also earned his DVSc. Dr. Wood earned his DVM from University of Prince Edward Island in Charlottetown, Prince Edward Island, Canada, and served as president of the American Society for Veterinary Clinical Pathology. His interests include hemostasis and molecular biomarkers of cancer in dogs. ■■■

**TOP 5 PAGE 51**

# FROM CLINICIAN'S BRIEF ON SOCIAL MEDIA

## WE ASKED ...

### Would you rather repeat veterinary school or high school?

**57%** Veterinary school

**43%** High school

"I enjoyed both until my senior year of veterinary school. I had great friends in high school, which made all the difference."—*Amy C*

"Neither; both were challenging in their own ways."—*Heather R*

"High school was the best time of my life. I was carefree and had zero responsibilities. I would go back in a heartbeat."—*Deanne M*

"Veterinary school, without a doubt! Those were the best years of my life, and I spent them with the best friends I have ever had."—*Cindy G*

### FOLLOW US

 [facebook.com/cliniciansbrief](https://facebook.com/cliniciansbrief)

 [@CliniciansBrief](https://twitter.com/CliniciansBrief)

 [clinicians.brief](https://instagram.com/clinicians.brief)

### Would you be in favor of state or federal regulations that limit or ban noncompete clauses in veterinary medicine?

**74%** Yes

**26%** No


"I do not accept positions with non-compete clauses."—*Anthony T*

"Regulations should only apply to individuals selling or starting practices, not associates moving from one clinic to another."—*Kim F*


"Limits maybe, but not a ban."  
—*Kate S*

"As a former owner and someone now job searching as an associate, I am in favor of limited time and radius noncompete clauses. It is not fair for an owner to invest in an associate who then opens a clinic next door, but it is also not fair that an associate who is treated poorly must move to get a new job."—*Danielle C*

### Do you routinely fast patients when treating acute pancreatitis?



### Do you administer an anticholinergic to combat bradycardia in dogs that have received dexmedetomidine as a premedication?



NOW AVAILABLE: AI BLOOD SMEAR

# SEE THE COMPLETE DIAGNOSTIC PICTURE FOR MORE COMPLETE CARE



## VETSCAN IMAGYST™ provides accurate, efficient AI-driven analysis of blood smears to supplement CBC results<sup>1</sup>

VETSCAN IMAGYST is a first-of-its-kind technology, offering blood smear, cytology and fecal diagnostics in a single platform. Using a compact scanner along with artificial intelligence (AI) technology and a network of remote expert clinical pathologists, VETSCAN IMAGYST delivers fast, efficient results so you can make important treatment decisions sooner.

**vetscan** IMAGYST™

Visit [vetscanimagyst.com](https://vetscanimagyst.com) to learn more

CBC=complete blood count.

Reference: 1. Data on file, Study No. D870R-US-21-045, 2021, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.  
© 2022 Zoetis Services LLC. All rights reserved. VTS-00499BR1

zoetis



# Shouldn't nutrition conversations be a little easier?



**YOUR TIME IS VALUABLE**, that's why we're creating more ways to support your nutrition recommendation so your patients get the care they deserve.

- 1** Redesigned packaging with easy-to-explain benefits
- 2** Hill's Quick Recommendation tool offers quick personalized nutrition plans
- 3** Our best taste technology ever so you can recommend with confidence

See all the ways we're ready to support you better than ever at [PrescriptionDiet.com/BetterThanEver](https://PrescriptionDiet.com/BetterThanEver)

## IN THIS ISSUE

### ON THE COVER

#### TOP 5

### Top 5 Signs of Patient Stress & Excitement on Clinical Pathology

R. Darren Wood, DVM, DVSc, DACVP (Clinical Pathology)

PG  
51



- 12 **HISTORY & PHYSICAL EXAMINATION**  
**Acute Lameness in a Pointer**  
Kristyn D. Broaddus, DVM, MS, DACVS
- 18 **DIAGNOSTIC/MANAGEMENT TREE**  
**Elevated Total Thyroxine in Cats**  
Heather Kvitko-White, DVM, DACVIM (SAIM)
- 20 **DIAGNOSTIC/MANAGEMENT TREE**  
**Low Total Thyroxine in Dogs**  
Patty Lathan, VMD, MS, DACVIM (SAIM)
- 55 **CASE IN POINT**  
**Eyelid Mass with Conjunctival & Periocular Swelling in a Cat**  
Sarah Bosch, DVM  
Susan Nelson, DVM  
Jessica Meekins, DVM, MS, DACVO  
Lisa M. Pohlman, DVM, MS, DACVP
- 61 **DIFFERENTIAL DIAGNOSIS**  
**Splenomegaly in Dogs**  
Elijah Ernst, DVM  
Karyn Harrell, DVM, DACVIM (SAIM)
- 65 **PROCEDURES PRO**  
**Digit Amputation in Dogs**  
Ka Yung Lee, DVM  
Judith Bertran, DVM, MS, DACVS (SA)





Nobivac® Canine 1-DAPPv+L<sub>4</sub>

● Vaccinate for core

● Protect against more

**NOBIVAC® CANINE 1-DAPPv+L<sub>4</sub>**—The only core + Leptospirosis vaccine that is effective against urinary shedding<sup>1</sup> and mortality<sup>2</sup> due to Leptospirosis

Bring convenience into practice with Nobivac® Canine 1-DAPPv+L<sub>4</sub>



To learn more, contact your Merck Animal Health sales representative or your distributor representative.

**Customer Service:** 1-800-521-5767  
(Monday–Friday, 9:00AM–6:00PM EST)

**Technical Services:** 1-800-224-5318  
(Monday–Friday, 9:00AM–7:00PM EST)

**Nobivac®**   
Protection unites us.

**References:** **1.** LaFleur RL, Dant JC, Tubbs AL, et al. Prevention of leptospiremia and leptospiruria following vaccination with a DAPPv + 4-way *Leptospira* combination vaccine. Presented at: Proceedings of the ISCAID Symposium; October 16–19, 2016; Bristol, UK. **2.** LaFleur RL, Dant JC, Wasmoen TL. Prevention of disease and mortality in vaccinated dogs following experimental challenge with virulent *Leptospira*. *J Vet Int Med.* 2011;25:747.

Copyright © 2021 Intervet, Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. US-NOV-21020022 409753

 **MERCK**  
Animal Health



## ON THE WEB

---

THIS MONTH'S FEATURED CLINICAL  
CONTENT AVAILABLE ONLY ONLINE

23 **FROM PAGE TO PATIENT**  
Tips & techniques from  
the research pages

03 **OUR  
AUTHORS**

06 **GET SOCIAL**  
Currently on *Clinician's Brief*  
social media

71 **ADVERTISERS  
INDEX**

72 **QUIZ CORNER**  
Test your knowledge

### RED LIGHT, GREEN LIGHT


#### Demodicosis & Secondary Bacterial Folliculitis in a Dog

Christina Monika Gentry, DVM,  
DACVD  
[brief.vet/bacterial\\_folliculitis](http://brief.vet/bacterial_folliculitis)



### PODCAST Feline Orthopedic Examination with Dr. Gordon-Evans

Wanda J. Gordon-Evans,  
DVM, PhD, DACVS, DACVSMR,  
explains why evaluating for  
musculoskeletal pain in cats  
is challenging but important.  
[brief.vet/orthopedic\\_](http://brief.vet/orthopedic_examination)  
[examination](http://brief.vet/orthopedic_examination)



---

Contact us at  
[editor@cliniciansbrief.com](mailto:editor@cliniciansbrief.com)

Articles archived at  
[digital.cliniciansbrief.com](http://digital.cliniciansbrief.com)

HISTORY & PHYSICAL EXAMINATION

# ACUTE LAMENESS IN A POINTER

---

**Kristyn D. Broaddus, DVM, MS, DACVS**

*Veterinary Specialists of Hanover  
Mechanicsville, Virginia*

**M**able, a 3-year-old spayed pointer, is presented with acute right pelvic limb lameness (right pelvic limb is non-weight-bearing) of 2-days' duration. She has no history of previous lameness. Her owner reports she had been standing on top of her doghouse ( $\approx 4.5$  ft off the ground) on the day she was injured.





▲ **FIGURE 1** Lateral view in which increased flexion of the tarsus independent of the stifle can be seen. The stifle is extended to compensate for loss of functional limb length.



▲ **FIGURE 2** A small skin laceration over the distal aspect of the lateral tibia is visible.

**Her owner reports she had been standing on top of her doghouse (≈4.5 ft off the ground) on the day she was injured.**



▲ **FIGURE 3** Caudal view in which the right pelvic limb has a dropped hock and there is a faintly bruised region over the gastrocnemius muscle bellies, where swelling is appreciated



▲ **FIGURE 4** Lateral radiograph of the affected right pelvic limb. No fractures or luxations are noted.

## History

Mable has congenital deafness but is otherwise healthy. Her BCS is 4/9. She was spayed at 6 months of age without complication. She receives routine flea, tick, and heartworm preventives. One other dog also lives in the household; both dogs are fed a commercially prepared raw diet. Mable's owner reports she is a high-energy dog that performs in agility competitions and has traveled throughout the southeastern coastal part of the United States.

## Physical Examination

On physical examination, Mable is tachycardic (180 bpm) and panting. Her temperature is 103.1°F (39.5°C). When she occasionally places the affected limb on the ground, she has a plantigrade stance. Mable is sedated due to her high stress level.

Pain is isolated to the hock region, and hyperflexion of the tarsus independent of the stifle is easily appreciated (*Figure 1*). During manual flexion of the tarsus, a crab claw appearance of the paw is noted. Diameter of the right Achilles tendon (ie, calcaneal tendon) is reduced by 25% relative to the left side. A firm knot is palpated deep in the gastrocnemius muscle bellies, a faint bruise is noted over the swelling on the caudal aspect of the thigh, and a 2-cm laceration is seen over the lateral aspect of the distal tibia (*Figures 2 and 3*). Radiographs of the right pelvic limb do not indicate fractures or luxations (*Figure 4*).

# How would you diagnose and treat this patient?

### QUESTION 1

**What is the most likely cause of this patient's mild temperature elevation?**

- A. Excitement and stress
- B. Tick-borne disease
- C. Inflammation from laceration on laterodistal hock
- D. Septic tarsal joint from consuming a raw diet

### QUESTION 2

**Which of the following imaging modalities would be most cost-effective for further initial evaluation of this patient's injury?**

- A. Radiography
- B. Ultrasonography
- C. CT
- D. MRI

### QUESTION 3

**Gastrocnemius, superficial digital flexor tendon, biceps femoris, gracillus, and semitendinosus define the \_\_\_\_\_ tendon.**

- A. Supraspinatus
- B. Suspensory
- C. Achilles
- D. Iliopsoas

### QUESTION 4

**What is the standard course of treatment to maximize possible full tarsal function return in a patient with acute, complete rupture of the Achilles tendon?**

- A. Ehmer sling for 6 weeks
- B. Partial tarsal arthrodesis
- C. Surgical repair of the Achilles tendon with 6 to 12 weeks of external coaptation via splint, cast, custom orthotic, or external fixator
- D. Injection of stem cells to the swollen region with cage rest for 4 weeks

### QUESTION 5

**True or false? External coaptation with a custom orthotic or splint is a nonsurgical option in a patient with a chronic, partial tear.**

- A. True
- B. False

### QUESTION 6

**What is the most relevant cause of the plantigrade/dropped hock stance in this patient?**


- A. Metatarsal fracture II-V
- B. Central tarsal bone fracture
- C. Achilles tendon rupture
- D. Degenerative myelopathy

**TURN THE PAGE TO SEE THE RESULTS**


### Treatment & Outcome

Surgery was performed to repair the full Achilles tendon rupture. The primary repair involved suturing the tendon ends to the calcaneus bone using bone tunnels and a 3-loop pulley with 0 polypropylene. Polypropylene mesh was used as additional reinforcement to reconstruct the Achilles tendon and its components (*Figures 5 and 6*).

External coaptation was provided via a cast that was transitioned to a caudal splint after 4 weeks. At 8 weeks, the splint was transitioned to a soft bandage. All bandages (ie, cast, splint, soft) were changed weekly. At 10 weeks, all external support was removed, and Mable’s activity was restricted for an additional 4 weeks. At her 16-week follow-up, Mable had a normal gait and stance. ■



▲ **FIGURE 5** Intraoperative view of the gastrocnemius tendons (2) that are torn and retracted into the muscle bellies



▲ **FIGURE 6** Intraoperative view of the lacerated gastrocnemius tendons being dissected out so they can be reattached to the calcaneus bone

### Suggested Reading

Baltzer W. Management of Achilles tendon rupture in the small animal (proceedings). *dvm360* website. Published March 31, 2008. Accessed January 4, 2022. <https://www.dvm360.com/view/management-achilles-tendon-rupture-small-animal-proceedings>

DeCamp CE, Johnston S, DeJardin L, Schaefer SL. Fractures and other orthopedic injuries of the tarsus, metatarsus, and phalanges. In: Piermattei DL, Flo GL, DeCamp CE, eds. *Brinker, Piermattei, and Flo's Handbook of Small Animal Orthopedics and Fracture Repair*. 4th ed. Elsevier; 2006:661-713.

Harasen G. Ruptures of the common calcaneal tendon. *Can Vet J*. 2006;47(12):1219-1220.

Lamb CR, Duvernois A. Ultrasonographic anatomy of the normal canine calcaneal tendon. *Vet Radiol Ultrasound*. 2005;46(4):326-330.

Lin M, Glass EN, Kent N. Utility of MRI for evaluation of calcaneal tendon rupture in a dog: case report. *Front Vet Sci*. 2020;7:602.

Meutsege FJ. The classification of canine Achilles tendon lesions. *Vet Comp Orthop Traumatol*. 1993;6(1):53-55.

### Answers

1:A, 2:B, 3:C, 4:C, 5:A, 6:C



# A FOOD ELIMINATION TRIAL IS THE GOLD STANDARD TO PRECISELY DIAGNOSE ADVERSE FOOD REACTIONS



**10 YEARS**

of successful partnership  
with veterinarians





# ELEVATED TOTAL THYROXINE IN CATS

Heather Kvitko-White, DVM, DACVIM (SAIM)

KW Veterinary Consulting

Kansas City, Missouri






\*Cats diagnosed with subclinical hyperthyroidism usually develop occult hyperthyroidism within one year.<sup>7</sup>

†Treatment failure in 1 out of 10 patients


# LOW TOTAL THYROXINE IN DOGS

Patty Lathan, VMD, MS, DACVIM (SAIM)  
Mississippi State University



\*Ninety-one percent of euthyroid sighthounds (eg, greyhounds) have low  $tT_4$  and 21% have low  $ft_4$ . Euthyroid greyhounds appear to have normal  $tT_3$  values; therefore, if  $tT_3$  is low in these patients, hypothyroidism or euthyroid sick syndrome are possible. To evaluate thyroid status in sighthounds, the author submits a full thyroid panel, including  $tT_4$ ,  $ft_4$ ,  $tT_3$ , and TSH; increased TSH and low  $tT_3$  confirm the diagnosis. Interpretation of normal TSH and low  $tT_3$  can be challenging. Therapeutic trial can be considered if clinically indicated.

Pursue diagnostics to determine cause of other abnormalities, followed by diagnostics for hypothyroidism after recovery from nonthyroidal illness



ft<sub>4</sub> = free thyroxine  
 TSH = thyroid stimulating hormone  
 t<sub>3</sub> = total triiodothyronine  
 t<sub>4</sub> = total thyroxine

**Reference**

1. Shiel RE, Brennan SF, Omodo-Eluk AJ, Mooney CT. Thyroid hormone concentrations in young healthy pretraining greyhounds. *Vet Rec.* 2007;161(18):616-619.

# Dechra Rewards

January 1 - June 30, 2022



Save up to **15% off** qualifying Dechra products!



## Step 1

**Scan the QR code above** or visit [www.DechraRewards.com](http://www.DechraRewards.com) to enroll in Dechra Rewards TODAY! (Enrollment deadline is May 1st, 2022.) If you are not yet a member of Vetcove, go to [vetcove.com/signup](http://vetcove.com/signup) to create a Vetcove account.



## Step 2

After your enrollment is verified and you've **completed your activation purchase** (see below for details)\*, you'll begin earning 1% rewards on qualifying Dechra products!



## Step 3

**Continue to shop** your favorite Dechra products as you always have, or purchase through Vetcove's direct checkout platform where it will be processed and shipped through your supplier of choice. You can view your goals and progress towards earning up to 15% on qualifying Dechra products at [www.vetcove.com](http://www.vetcove.com).

Scan the QR code or visit [DechraRewards.com](http://DechraRewards.com) for the full terms and conditions.

\*You'll earn rewards after your first purchase of any of the following brands between January 1st through June 30th, 2022: Osumnia® (florfenicol, terbinafine, betamethasone acetate), Mirataz® (mirtazapine transdermal ointment), Porus® One, Clavacillin® (amoxicillin trihydrate/clavulanate potassium) Veterinary Tablets, Enroquin® Flavored Tablets (enrofloxacin), Dexmedesed® (dexmedetomidine hydrochloride) Sterile Injectable Solution, Butorphanol Tartrate Injection, Rompun® (Xylazine) Injectable, SucroMate® Equine (deslorelin acetate) Sterile Suspension, or Zimeta® (dipyron injection).

Dechra is a registered trademark of Dechra Pharmaceuticals PLC. Rompun, Osumnia, and Mirataz are registered trademarks of Dechra Limited. Dexmedesed, Clavacillin, and Enroquin are registered trademarks of Dechra Veterinary Products. SucroMate, Porus, and Zimeta are registered trademarks of their respective owners.

00SD-DEC22083-0322

Designed to bridge the gap between research pages and daily practice protocol, the following pearls offer tips and techniques to grow the general practitioner's clinical excellence.



## 24 **Neutrophil-to-Lymphocyte Ratio in Canine Inflammatory Bowel Disease**

Jonjo Reece, DVM  
Mary Anna Labato, DVM, DACVIM (SAIM)

## 26 **Congenital Ocular Malformations**

Shelby Reinstein, DVM, MS, DACVO

## 28 **Screening Dogs for Hip Dysplasia**

Heather L. Troyer, DVM, DABVP, CVA, CVPP

## 31 **Effect of Dietary Starch Sources on Canine Lipidemia**

Camille Torres-Henderson, DVM, DABVP (Canine/Feline)

## 34 **A Comparison of Nalbuphine, Butorphanol, & Morphine in Dogs**

Andrew K. Claude, DVM, DACVAA

## 38 **Potential Tool for Prognosticating in Canine Mammary Gland Tumors**

Cheryl Balkman, DVM, MS, DACVIM (Internal Medicine, Oncology)

## 41 **Screening Liver & Kidney Values Prior to NSAIDs**

Faith I. Buckley, DVM, DACVIM (SAIM)

## 45 **Greetings, Departures, & Canine Separation Anxiety**

Katherine A. Houpt, VMD, PhD

## 49 **Surgical Site Infection Following Extracapsular Cranial Cruciate Ligament Repair**

Jonathan Miller, DVM, MS, DACVS

### RESEARCH NOTES

## 25 **Chronic Enteropathy in French Bulldogs & Miniature Dachshunds**

## 27 **Detecting Ionized Hypocalcemia**

## 42 **Transmittable Blood-Borne Disease from Canine Blood Donors**

## 46 **Efficacy of a Nonnucleoside Inhibitor Against FIP Virus**

# Identifying and Managing High-Risk Cats: How Early Intervention Helps Avert Clinical Diabetes



**Chen Gilor, DVM, PhD, DACVIM (SAIM)**

Associate Professor, Small Animal Internal Medicine  
Department of Small Animal Clinical Sciences  
College of Veterinary Medicine  
University of Florida

**Q** Your research has focused on identifying strategies to delay or prevent the need for insulin therapy in pets. Why do you feel this approach is so important?

**A** I want to do right by my patients, and disease prevention is better for them than any treatment strategy. Insulin therapy can be dangerous, complicated and expensive. Not only are there risks for the diabetic patient, including hypoglycemia and diabetic ketoacidosis, but insulin administration and monitoring of pets with insulin-dependent diabetes can be quite burdensome for the pet owner.

**Q** The terms “prediabetes” and “subclinical diabetes” are used to describe cats at risk of clinical diabetes. What do these terms mean?

**A** Prediabetes and subclinical diabetes are not well defined in veterinary medicine. Although risk criteria for prediabetes have been suggested, they have not yet been tested in a prospective, longitudinal study. The diagnosis of subclinical diabetes is applied to patients with glucose and/or glycated protein (fructosamine, A1C) measurements that are consistent with diabetes but not yet displaying clinical signs of overt diabetes or insulin dependence.<sup>1</sup>

It’s fair to say that cats probably follow a similar course to humans with Type 2 diabetes, in that during the prediabetic and subclinical phases, it’s still possible to change course. Weight management is important: Although most obese cats will not develop diabetes, we know that these cats are at increased risk of developing diabetes because of the association of obesity with insulin resistance.

Practitioners can be proactive with patients they believe to be at risk. The three pieces to the feline diabetes puzzle are: (1) **preserve beta cell function and avert its further loss**; (2) **decrease insulin resistance**; and (3) **decrease carbohydrate consumption** (see Figure 1).

**Q** What steps can practitioners take to identify and manage cats at risk?

**A** Regularly monitor cats for changes in blood glucose and other parameters. A caveat to this is that stress can cause temporary elevation of blood glucose, causing practitioners to sometimes dismiss high glucose readings. Fructosamine levels can be measured, although if a cat has an average blood glucose of around 160, a fructosamine test may not be sensitive enough to determine if that patient has diabetes. A more sensitive parameter to measure might be A1C levels. When I see high blood glucose readings—

especially with an obese cat—I typically run a hemoglobin A1C test.

**Facilitate weight loss.** In addition to nutritional management, there are safe, effective drugs that are useful. I emphasize to clients that if the intervention can prevent the cat from developing diabetes, it’s worth it.

**Recommend a therapeutic diet.** If the cat is not already on a **low-carbohydrate diet**, such as one of the canned Purina® Pro Plan® Veterinary Diets DM Dietetic Management® Feline Formulas, they should start. Diets such as these have high protein content to help maintain lean body mass, which is key as the cat loses weight.

**Preserve beta cell function and avert its further loss.** This is currently the most challenging step. Aggressive management of hyperglycemia and hyperlipidemia might help reduce beta cell glucolipotoxicity. Drugs in the GLP-1 receptor agonist family likely help in beta cell preservation and have been studied in cats, with similar effects noted in people and other models of diabetes.<sup>2</sup>

Weight loss and preserving beta cell function are also key to achieving remission in a diabetic cat. Veterinarians often ask me for my recommendations on the best insulin or diet for a particular patient with diabetes and how to achieve remission. However, I believe that successful management of patients with diabetes—as well as diabetes prevention—isn’t really about these kinds of isolated choices. It’s about understanding all of the options available and determining the right combination for the individual owner and patient with whom you’re working.

## Preventing clinical diabetes in at-risk cats.




Figure 1.



<sup>1</sup> European Society of Veterinary Endocrinology, Project ALIVE, Subclinical diabetes mellitus in dogs and cats. <https://www.esve.org/alive/search.aspx> (Accessed Jan. 26, 2022)

<sup>2</sup> Gilor C, Rudinsky AJ, Hall MJ. New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs. *J Feline Med Surg.* 2016 Sep;18(9):733-43.

# Veterinary/Client Commitment Key to Managing Diabetic Cats



**Jocelyn Mott, DVM,  
DACVIM (SAIM)**

Diabetes Fellow  
University of Florida

Successful management of cats with diabetes requires close supervision, regular monitoring, dedication and excellent teamwork by the cat's owner and veterinarian. A therapeutic and dietary protocol should be tailored to fit both the medical needs of the individual cat and the abilities, wishes and lifestyle of the owner. Many owners who initially are hesitant about insulin therapy become more comfortable and committed with time and experience. Some owners want to do everything possible and, in those cats, tight glycemic control with the goal of remission would be appropriate. Clients should be informed that most diabetic cats need lifelong insulin therapy and monitoring.

## Here are my recommendations:



### 1. Encourage observation.

Improvement or worsening of signs can be an indication that a cat's insulin requirements may be changing. Owners should monitor for improvement in signs

such as decreased water consumption, decreased urine production, and changes in appetite, weight and activity levels.

Signs of worsening glycemic control can include decreased appetite or anorexia, lethargy, and/or dramatic weight loss or weight gain. Owners can report these signs to their veterinarians to inform decisions about insulin adjustments.

Clients should be educated to watch for signs of hypoglycemia, such as disorientation, ataxia or seizures—and, if these occur, to inform their veterinarian immediately. Owners should also keep Karo syrup or dextrose paste on hand to administer as they seek immediate veterinary care.



### 2. Emphasize appropriate nutrition.

For diabetic cats, I typically recommend therapeutic low-carbohydrate diets such as Purina® Pro Plan® Veterinary Diets

DM Dietetic Management® Feline Formulas. If a cat won't eat a therapeutic diabetic low-carbohydrate diet, I may recommend a change to a lower carbohydrate canned diet than he or she was eating when the diabetes developed.

For an overweight diabetic cat, I'll first recommend a therapeutic diabetic low-carbohydrate diet that is also indicated for weight loss. However, if the cat does not lose

weight on that diet, I may recommend a therapeutic weight management diet, then switch to a therapeutic diabetic diet after weight loss has been achieved.



### 3. Discuss at-home glucose monitoring.

Diabetic cats need regular monitoring of glucose levels to maintain good glycemic control and maintain the correct insulin dose. Continuous blood glucose monitoring devices are a great way to monitor cats at

home and can make hospital visits less frequent. If clients want to do home blood glucose curves, I advise they use a glucometer designed specifically for pets. However, clients should only adjust insulin doses based on their veterinarian's directions. If home monitoring is not an option for the owner, then blood glucose curves and/or fructosamine levels should be performed regularly with their veterinarian.



### 4. Schedule regular check-ups.

Ongoing veterinary appointments are needed to monitor patients with feline diabetes and to catch any developing comorbidities—such as pancreatitis, urinary tract infections, hyperadrenocorticism,

renal disease, dental disease or obesity—early. Even if owners are monitoring the cat's blood glucose levels or using continuous glucose monitoring at home and the cat appears well controlled, I still like to examine and reassess the cat about every three months.



### 5. Communicate between clinic visits.

Regular reinforcement via phone calls and/or emails from their veterinary team can help ensure that clients follow their cat's treatment and monitoring protocols.

If a technician on staff shows interest in managing cats with diabetes, he or she can be a valuable resource.

Ensuring that clients feel confident in their ability to care for their diabetic pet is essential. While reaching this point can take time, the process can be rewarding for all concerned.



## The Care and Feeding of Diabetic Cats Check out this Nutrition Brief

How many daily calories are optimal for an obese, diabetic cat?  
Must insulin injections always be given at mealtime?  
How can owners monitor their diabetic cat's weight and body condition at home?  
Check out the Purina Institute's CentreSquare toolkit at [purinainstitute.com/catdiabetes](http://purinainstitute.com/catdiabetes) or scan the QR code to find answers to these questions and more.



# Diabetes and Diet: Answering FAQs About Feline Diabetes Management



**Emily Cross, DVM,  
DABVP (Canine/Feline)**  
Director of Publications  
and Education,  
Purina Institute  
Nestlé Purina PetCare

Here are some common queries from veterinarians about feeding cats with diabetes.

## What is the optimal feeding frequency for diabetic cats?

Administering insulin with a morning and evening meal is commonly recommended for feline patients—if the client is willing and the timing works for patient and owner. However, if an owner feeds their cat *ad libitum* or the cat is picky and needs fresh food offered more frequently during the day, I don't dictate a cat only be fed when insulin is administered. One study showed cats do not have the same postprandial hyperglycemia seen in canine and human diabetics.<sup>1</sup>

## Why is it important to maintain cats with diabetes on a therapeutic diet after they've achieved remission?

Fortunately, diet is something we can control in our patients with diabetes. However, it is essential that clients view their cat's therapeutic diet as a lifelong form of therapy.

A client may think that if his or her cat is in diabetic remission, the problem is fixed and the cat can resume eating

the previously fed over-the-counter (OTC) diet. A cat in remission might appear normal, but the therapeutic high-protein/low-carbohydrate diet must continue to be fed because an increase in digestible carbohydrate could lead to dysregulated blood glucose and a need to reinstitute exogenous insulin.

Some clients will ask if they can use a high protein/low carbohydrate OTC canned diet. While this strategy is possible, the client should understand that such diets are designed for healthy cats, not cats with the specific requirements of a diabetic. In addition, if the diet is reformulated and the type or amount of carbohydrate is changed, that could be an issue for a cat with diabetes. To manage conditions, therapeutic diets should be used under the guidance of a veterinarian.

## Can diabetic cats lose weight on a high-calorie dry diet formulated for management of cats with diabetes?

If a diabetic patient is obese or overweight, then weight loss is a priority and canned food may offer a benefit. I recommend owners try a wet therapeutic diet such as Purina® Pro


Plan® Veterinary Diets DM Dietetic Management® canned Feline Formula, which is high in protein, moderate in fat and low in carbohydrate. Moisture can help dilute calories, increasing the volume of food consumed per kilocalorie. Even cats that are used to eating dry food can often be transitioned to all canned if done over time.

However, if an obese diabetic cat strongly prefers dry food, I may recommend a calorie-restricted dry diet like Purina® Pro Plan® Veterinary Diets OM Overweight Management® Feline Formula, which is higher in carbohydrate compared to DM canned or dry, and use insulin to maintain diabetic control. Ultimately the cat may be able to transition to lower-carbohydrate DM dry once weight-loss goals have been reached. However, client education is a must in such cases, given that the volume of DM fed will be significantly less than that of OM.

<sup>1</sup> Martin GJ, Rand JS. Food intake and blood glucose in normal and diabetic cats fed *ad libitum*. *J Feline Med Surg*. 1999;1(4):241-251. doi:10.1053/jffms.1999.0052.

## Feline Diabetes by the Numbers

Overweight cats have  
**4.6x** greater risk of diabetes  
than cats in ideal body condition.



Approximately **1 in 5**  
obese cats >8 years of  
age are prediabetic.

Best odds of diabetes remission occur  
if glycemic control is achieved within  
**6 months** of diagnosis.



**25% to 30%**  
of cats in remission will relapse  
and require that insulin be restarted.

## Key Takeaways

- Practitioners can reduce risk and decrease insulin resistance in cats by recommending low-carbohydrate diets and weight loss for obese cats.
- A diet change—either to a therapeutic low-carbohydrate diet or to a therapeutic weight-loss diet for overweight cats—is an essential step for managing patients with diabetes.
- Clients should view a therapeutic diet as a lifelong form of therapy for their diabetic cats, even if the cats are in remission.

**PURINA**  
**PRO PLAN**  
**VETERINARY**  
**DIETS**

WHAT IF...


YOU COULD PRESCRIBE  
PEACE OF MIND?



**A diabetic diagnosis doesn't just mean new prescriptions for cats.** It can mean new worries for clients. With trusted DM Dietetic Management® formulas and new GlucoTest™ Feline Urinary Glucose Detection System, you're not just recommending products...you're sending them home with reassurance.



High protein and low carbohydrate  
to help support the unique  
nutritional needs of diabetic cats



Easy-to-use home  
monitoring kit to  
detect glucosuria

LEARN MORE AT [PURINAPROPLANVETS.COM](http://PURINAPROPLANVETS.COM)

1-800-222-8387 (8:00 AM - 6:00 PM CST M-F) | Talk to your Purina Veterinary Consultant

\*Based on dollar sales of Purina® Pro Plan® Veterinary Diets DM Dietetic Management® formulas as a percentage of total diabetes therapeutic diet sales as reported by IDEXX, Vet Panel Market Database, 52 W/E 10/09/2021.  
Purina trademarks are owned by Société des Produits Nestlé S.A.

**PURINA**

Your Pet, Our Passion.®

# Neutrophil-to-Lymphocyte Ratio in Canine Inflammatory Bowel Disease

Jonjo Reece, DVM

Mary Anna Labato, DVM, DACVIM (SAIM)

Cummings School of Veterinary Medicine at Tufts University

**During inflammatory states, the neutrophil count may increase, whereas the lymphocyte count may decrease.<sup>3</sup>**

## In the literature

Benvenuti E, Pierini A, Gori E, Lucarelli C, Lubas G, Marchetti V. Neutrophil-to-lymphocyte ratio (NLR) in canine inflammatory bowel disease (IBD). *Vet Sci.* 2020;7(3):141.

## FROM THE PAGE ...

Canine inflammatory bowel disease (IBD) is characterized by idiopathic intestinal inflammation and lack of response to diet and antibiotic treatments.<sup>1</sup> Histopathology of the intestinal tract and response to immunosuppressive therapy are required for definitive diagnosis. Factors associated with negative outcomes for dogs with IBD include the chronic canine enteropathy clinical activity index (CCECAI), a high endoscopic score in the duodenum, hypocobalaminemia (<200 ng/L), and hypoalbuminemia (<20 g/L).<sup>2</sup>

Predictive markers are still needed to classify IBD-affected dogs into risk groups. One such prospective marker is the neutrophil:lymphocyte ratio (NLR). During inflammatory states, the neutrophil count may increase, whereas the lymphocyte count may decrease.<sup>3</sup> NLR is an accessible parameter that can easily be calculated as a ratio between absolute neutrophils and lymphocytes using a WBC count differential.<sup>3</sup> In studies of human patients with IBD, NLR appeared to be higher in patients with active disease.<sup>4</sup>

This retrospective study evaluated the clinical and prognostic significance of NLR in dogs with IBD. NLR of healthy control dogs ( $n = 150$ ) was compared with dogs with IBD ( $n = 41$ ). The correlation between NLR and several variables, including CCECAI and endoscopic histology scores, was investigated. After one month of treatment with immunosuppressive therapy, differences in NLR between responders and nonresponders were assessed.

Results revealed that dogs with IBD had higher median NLRs than the control dogs (4.78 vs 3), although most dogs with IBD had neutrophil and lymphocyte counts within reference intervals. There was a moderate positive correlation between NLR and CCECAI at the time of admission, which supports the potential use of NLR as a marker of clinical disease severity in canine IBD. NLR seemed to be negatively correlated with total protein, albumin, and cholesterol levels. NLR was higher in dogs diagnosed with protein-losing enteropathy, potentially due to loss of lymphocytes through ruptured lacteals.<sup>4</sup> The only significant histologic parameter associated with NLR was the presence of lacteal dilation. In the study population, NLR did not differ significantly between endoscopic or histologic score groups. After one month of immunosuppressive therapy, the median NLR was significantly higher in nonresponders than responders (12.23 vs 4.58).

### ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Because of its poor sensitivity and specificity, increased NLR should not be used as the sole diagnostic criteria for canine IBD or lymphangiectasia. Although NLR can be used to further support suspicion of these disorders, histologic diagnosis is still required.
- 2** NLR has potential use as a marker of disease severity in canine IBD as well as for clinical monitoring of therapeutic response in cases of chronic enteropathies. NLR can be easily calculated by dividing the absolute neutrophil count by the absolute lymphocyte count using the results of routine blood work.
- 3** NLR can be impacted by stress and chronic disease states. The extent of impact has not been examined, and further studies are needed.

### References

1. Dandrieux JRS. Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same? *J Small Anim Pract.* 2016;57(11):589-599.
2. Allenspach K, Wieland B, Gröne A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. *J Vet Intern Med.* 2007;21(4):700-708.
3. Blackwood L. Disorders of leukocytes. In: Villiers E, Ristic J, eds. *BSAVA Manual of Canine and Feline Clinical Pathology.* 3rd ed. British Small Animal Veterinary Association; 2016:67-93.
4. Acarturk G, Acay A, Demir K, Ulu MS, Ahsen A, Yuksel S. Neutrophil-to-lymphocyte ratio in inflammatory bowel disease – as a new predictor of disease severity. *Bratisl Lek Listy.* 2015;116(4):213-217.

## Research Note: Chronic Enteropathy in French Bulldogs & Miniature Dachshunds

Chronic enteropathy (CE) in dogs is categorized into subtypes according to responsiveness to food trials, antibiotics, or steroids/immunosuppressants. CE unresponsive to any of these treatments is classified as *nonresponsive enteropathy*. Differentiating subtypes can be difficult due to clinical and histologic similarities. The major histocompatibility complex (MHC) class II genotype in humans and the canine MHC (ie, dog leukocyte antigen [DLA]) genotype have been associated with several immune-mediated conditions.

This study examined the potential for determining susceptibility to refractory CE through identification of risk and protective genotypes in French bulldogs and miniature dachshunds. No statistical difference was noted between dachshunds and controls. In French bulldogs, several significant associations were found between DLA class II genotypes and refractory CE. These findings support an immunogenetic component of CE in French bulldogs. Further studies involving larger sample sizes and different breeds may aid in early diagnosis, treatment, and prevention of CE through epigenetic approaches and breeding.

### Source

Nakazawa M, Miyamae J, Okano M, et al. Dog leukocyte antigen (DLA) class II genotypes associated with chronic enteropathy in French bulldogs and miniature dachshunds. *Vet Immunol Immunopathol.* 2021;237:110271.



# Congenital Ocular Malformations

Shelby Reinstein, DVM, MS, DACVO

*VETgirl*

*Bucks County, Pennsylvania*

**These malformations result from abnormal embryonic development, which may occur spontaneously or due to gestational teratogens, including both genetic and nongenetic factors.**

## In the literature

Saraiva IQ, Delgado E. Congenital ocular malformations in dogs and cats: 123 cases. *Vet Ophthalmol.* 2020;23(6):964-978.

## FROM THE PAGE ...

Congenital ocular malformations are rare in dogs and cats and include abnormalities present at birth, after the eye opens, or at  $\approx$ 6 to 8 weeks of age. These malformations result from abnormal embryonic development, which may occur spontaneously or due to gestational teratogens, including both genetic and nongenetic factors. Some congenital ocular disorders have been identified as heritable within a breed (eg, collie eye anomaly) and form the basis for breeding recommendations by veterinary ophthalmologists. In humans, congenital ocular malformations are a leading cause of childhood blindness, and veterinary models are often used to investigate disease mechanisms and treatment options.

This study sought to identify the prevalence and epidemiology of congenital ocular malformations in dogs and cats presented to a veterinary teaching hospital in Portugal. A prospective and retrospective evaluation of medical records included data on age, breed, sex, medical history, reason for presentation, clinical findings, vision impairment, and treatment options.

Of the 32,974 dogs and 13,977 cats evaluated, 103 (0.3%) dogs and 20 (0.1%) cats were diagnosed with a congenital malformation in one or both eyes. The most commonly identified ocular malformations in both dogs and cats were congenital cataracts, microphthalmia, and persistent pupillary membranes. Among dogs with ocular dermoids, French bulldogs were significantly overrepresented (75% of cases). No sex predisposition was identified for any congenital ocular malformation.

Surgery was performed on 25 dogs to address congenital ocular malformations. The most common procedures were ocular dermoid removal (12 dogs) and cataract phacoemulsifica-

tion with intraocular lens implantation (9 dogs). Four cats underwent surgery (3 for microphthalmos and/or entropion and one for enucleation due to congenital glaucoma).

This study highlighted the rarity of congenital ocular malformations in dogs and cats and provided insight into these conditions. It is important to be aware of the most common congenital eye conditions, as treatment options may be available. Additional exploration of the possible hereditary nature of ocular dermoids in French bulldogs is warranted.

### ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Congenital ocular malformations are rare in dogs and cats. The most frequently diagnosed conditions are congenital cataracts, microphthalmia, and persistent pupillary membranes. Congenital cataracts and microphthalmia may affect vision, and referral to a veterinary ophthalmologist for surgical evaluation is recommended.
- 2** Persistent pupillary membranes vary in appearance and are named based on the structures with which they associate (ie, iris-to-iris, iris-to-lens, iris-to-cornea). In addition, persistent pupillary membranes may simply appear as a cluster of pigment on the anterior lens capsule without overt pigment strands; this type of persistent pupillary membrane is common in dogs, especially cocker spaniels. The most common type of persistent pupillary membrane in cats is iris-to-cornea, and a corneal opacity is usually present at the endothelial attachment point.
- 3** French bulldogs appear to be predisposed to ocular dermoids. Clinically, dermoids are typically located on the eyelids, conjunctiva, or limbus of the cornea. The most common complication is corneal irritation, and surgery to remove the dermoid is often recommended.

### Suggested Reading

- Badanes Z, Ledbetter EC. Ocular dermoids in dogs: a retrospective study. *Vet Ophthalmol*. 2019;22(6):760-766.
- Cook CS. Ocular embryology and congenital malformations. In: Gelatt KN, Gilger BC, Kern TJ, eds. *Veterinary Ophthalmology*. 5th ed. John Wiley & Sons; 2013:3-38.
- Glaze MB. Congenital and hereditary ocular abnormalities in cats. *Clin Tech Small Anim Pract*. 2005;20(2):74-82.

## Research Note: Detecting Ionized Hypocalcemia

Serum total calcium (tCa) exists in 3 fractions: protein-bound (primarily albumin), ionized (iCa), and complexed. iCa is the most clinically relevant fraction of tCa for evaluating calcium homeostasis; however, methods for measuring iCa in clinical practice are not always readily available. Although formulas to adjust tCa to correct for serum protein concentration have been evaluated, these formulas are not designed for and do not predict iCa in the general population. These formulas were hypothesized to be predictive of iCa in patients with hypoalbuminemia but not hyperphosphatemia, which can affect the complexed fraction of calcium.

A retrospective review of 262 dogs with serum albumin concentration  $\leq 2.5$  g/L and serum phosphorus concentration  $\leq 5$  mg/dL calculated adjusted calcium concentration (aCa) using the formula:

$$\text{aCa} = \text{tCa (mg/dL)} - \text{serum albumin concentration (g/dL)} + 3.5 \text{ (g/dL)}$$

Results demonstrated that low aCa was useful for accurate detection of ionized hypocalcemia in this population of dogs.

### Source

De Witte F, Klag A, Chapman P. Adjusted calcium concentration as a predictor of ionized hypocalcemia in hypoalbuminemic dogs. *J Vet Intern Med*. 2021;35(5):2249-2255.

# Screening Dogs for Hip Dysplasia

Heather L. Troyer, DVM, DABVP, CVA, CVPP  
Oradell Animal Hospital  
Paramus, New Jersey

**Hip joint laxity can lead to abnormal acetabular contact with the femoral head, which can exacerbate the disease.**

## In the literature

Haney PS, Lazarowski L, Wang X, et al. Effectiveness of PennHIP and Orthopedic Foundation for Animals measurements of hip joint quality for breeding selection to reduce hip dysplasia in a population of purpose-bred detection dogs. *J Am Vet Med Assoc.* 2020;257(3):299-304.

## FROM THE PAGE ...

Although hip dysplasia is a malformation of the hip joint, the consequent degenerative joint disease (DJD) is largely caused by the dynamic and abnormal articulation of the femoral head within the acetabulum. Hip joint laxity can lead to abnormal acetabular contact with the femoral head, which can exacerbate the disease. DJD is the primary reason for medical intervention in older dogs, as pain and decreased range of motion typically impact daily activities, particularly exercise and mobility, posturing to urinate and defecate, overall engagement, and advanced exercises (eg, agility, detection/law enforcement work, guide dog work).

This study details the PennHIP scoring system for detecting congenital hip dysplasia and suggests that quantifying hip laxity is a key factor in improving hip joint quality scores. PennHIP evaluations are performed by PennHIP specialists to measure passive hip joint laxity of the pelvis under compression or distraction, which changes the femoral head displacement from the center of the acetabulum. The measured distance is then divided by the radius of the femoral head, resulting in a unitless measure of joint laxity (ie, the distraction index [DI]), which is more accurately predictive of DJD risk than subjective methods (eg, the Orthopedic Foundation for Animals [OFA] system—a 7-point scoring system that describes nondysplastic hips as excellent, good, or fair and dysplastic hips as mild, moderate, or severe).<sup>1,2</sup> The PennHIP index is most useful in patients <24 months of age and in females not in estrus, as hormonal changes have been shown to directly correlate with hip laxity.<sup>3</sup>

## ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** DJD is the most common reason military working dogs >5 years of age are discharged.<sup>4</sup> Attention to multimodal pain management, including joint restorative therapies, is important in these patients.
- 2** When screening for hip dysplasia, it is key to obtain quality radiographs taken with the patient under sedation. The positive predictive value of standard OFA positioning may be enhanced by the addition of DI values to OFA hip joint scores.
- 3** Limitations exist when screening young dogs for hip dysplasia. Environmental factors, estrus, breed, body weight, frame size, history of strenuous activity, and poor muscle mass can contribute to joint laxity. It is thus important to educate pet owners about the specific needs of their dog when deciding whether radiography is warranted to evaluate hip integrity.

## References

- Lust G, Williams AJ, Burton-Wurster N, et al. Joint laxity and its association with hip dysplasia in Labrador retrievers. *Am J Vet Res.* 1993;54(12):1990-1999.
- Smith GK, Mayhew PD, Kapatkin AS, McKelvie PJ, Shofer FS, Gregor TP. Evaluation of risk factors for degenerative joint disease associated with hip dysplasia in German shepherd dogs, golden retrievers, Labrador retrievers, and rottweilers. *J Am Vet Med Assoc.* 2001;219(12):1719-1724.
- Steinetz BG, Williams AJ, Lust G, Schwabe C, Büllesbach EE. Transmission of relaxin and estrogens to suckling canine pups via milk and possible association with hip joint laxity. *Am J Vet Res.* 2008;69(1):59-67.
- Evans RI, Herbold JR, Bradshaw BS, Moore GE. Causes for discharge of military working dogs from service: 268 cases (2000-2004). *J Am Vet Med Assoc.* 2007;231(8):1215-1220.

## Suggested Reading

Antech imaging services. The key to reducing canine hip dysplasia. AIS website. Accessed January 2021. [https://antechimaging.com/antechweb/pdf/AIS\\_PennHIP\\_Brochure\\_2015.pdf](https://antechimaging.com/antechweb/pdf/AIS_PennHIP_Brochure_2015.pdf)

**RECONCILE® (fluoxetine hydrochloride) Chewable Tablets** For complete prescribing information, see full package insert. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. **Indications:** RECONCILE chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. **Contraindications:** RECONCILE chewable tablets should not be used in dogs with epilepsy or history of seizures, nor given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines). RECONCILE chewable tablets should not be given in combination with, or within 14 days of discontinuing, a monoamine oxidase inhibitor (MAOI). RECONCILE chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs. Observe a 6-week washout interval following discontinuation of therapy with RECONCILE chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or its metabolite, norfluoxetine. **Human Warnings:** Not for use in humans. Keep out of reach of children. In case of accidental ingestion seek medical attention immediately. **Precautions:** RECONCILE chewable tablets are not recommended for the treatment of aggression and have not been clinically tested for the treatment of other behavioral disorders. Studies in breeding, pregnant or lactating dogs and in patients less than 6 months of age have not been conducted. Seizures may occur in dogs treated with RECONCILE chewable tablets, even in dogs without a history of epilepsy or seizures (see **Adverse Reactions**). Before prescribing RECONCILE chewable tablets, a comprehensive physical examination should be conducted to rule out causes of inappropriate behavior unrelated to separation anxiety. RECONCILE chewable tablets have not been evaluated with drugs that affect the cytochrome P450 enzyme system and should be used with caution when co-administered with any drug that affects this system. Studies to assess the interaction of RECONCILE chewable tablets with tricyclic antidepressants (TCAs) (e.g., amitriptyline, clomipramine) have not been conducted. The minimum washout period to transition dogs from TCAs to RECONCILE chewable tablets has not been evaluated. Data demonstrate that TCAs are cleared 4 days following discontinuation.<sup>1,2</sup> **Adverse Reactions:** In two North American field studies involving 427 dogs, the following adverse reactions were observed at a rate of  $\geq 1\%$  in dogs treated with RECONCILE chewable tablets (n=216): calm/lethargy/depression (32.9%), decreased appetite (26.9%), vomiting (17.1%), shaking/shivering/tremor (11.1%), diarrhea (9.7%), restlessness (7.4%), excessive vocalization (including whining) (6.0%), aggression (4.2%), otitis externa (2.8%), disorientation (2.3%), incoordination (2.3%), constipation (1.4%) and excessive salivation (1.4%). **Other Adverse Reactions: Seizures:** One of 112 dogs in the control group and three of 117 dogs that received RECONCILE chewable tablets experienced the serious adverse reaction of seizures during or after the end of the treatment period. One dog that was treated with RECONCILE chewable tablets experienced two seizures 10 days after the end of therapy and, despite escalating phenobarbital doses, died in status epilepticus approximately six months after the first seizure. In the second study, one of 99 dogs treated with RECONCILE chewable tablets and one of 99 dogs treated with the control tablet experienced the serious adverse reaction of seizures. Lastly, in a European multi-site study, one dog treated with a daily dose of 0.4 mg/kg for one month experienced one seizure one week after discontinuing therapy. **Weight loss:** In field studies, a weight loss  $\geq 5\%$  (relative to pre-study body weight) was observed in 58 (29.6%) of dogs treated with RECONCILE chewable tablets and 24 (13.0%) of control dogs. No dogs were withdrawn from clinical studies due to weight loss alone. **Dose reduction:** Twenty dogs in the RECONCILE chewable tablet group and five control dogs required a dose reduction due to unacceptable adverse reactions, the majority intermittent and mild, generally anorexia, vomiting, shaking and depression. Lowering the dose eliminated or reduced the severity of these reactions in the RECONCILE chewable tablet group only, while resumption of the full dose resulted in a return of the initial adverse reactions in approximately half the affected dogs. One dog experienced recurrence of severe adverse reactions, which necessitated withdrawal from the study. Additionally, two dogs required a second dose reduction of RECONCILE chewable tablets. **Post Approval Experience (Rev. 2010):** The following adverse events are based on post-approval adverse drug experience reporting with RECONCILE® chewable tablets. Not all adverse reactions are reported to FDA CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data. The following adverse events are listed in decreasing order of reported frequency: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination and hypersalivation. For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Pegasus Laboratories at 1-800-874-9764. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/reportanimadlae>. **Effectiveness:** In one randomized multi-centered, double-blinded, vehicle-controlled study of 8 weeks' duration, 229 dogs were evaluated at 34 investigative sites in the United States and Canada. One hundred seventeen dogs were randomized to 1-2 mg/kg/day of RECONCILE chewable tablets and 112 dogs were randomized to the control group. Both groups underwent concurrent behavior modification. In seven of the eight weeks, the percentage of dogs with improved overall separation anxiety scores was significantly higher ( $p < 0.05$ ) among dogs treated with RECONCILE chewable tablets compared to dogs that received the control tablet. At the end of the study, 73% of dogs treated with RECONCILE chewable tablets showed significant improvement ( $p=0.010$ ) as compared to 51% of dogs treated with behavior modification alone. Dogs treated with RECONCILE chewable tablets also showed improvement in destructive behavior, excessive vocalization and restlessness over dogs that received the control tablet. In addition, dogs in both groups experienced improvement in inappropriate urination, inappropriate defecation, excessive salivation, excessive licking/grooming, shaking/shivering and depression. Overall separation anxiety severity scores improved more rapidly for dogs taking RECONCILE chewable tablets than those dogs receiving the control tablet. The same effect was also noted for the individual scores for excessive vocalization and depression. **To obtain full product information please call 800-874-9764 or visit [Reconcile.com](http://Reconcile.com) • Approved by FDA under NADA # 141-272 • Pegasus Laboratories, Inc.**

<sup>1</sup> Plumb DC. Amitriptyline. *Veterinary Drug Handbook 5th Edition (Pocket Edition)*. Iowa State Press. Ames, IA. Page 39, 2002. <sup>2</sup>Hewson CJ, et al. The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily doses of clomipramine. *J Vet Pharmacol Therap* 21 :214-222, 1998.



# Dogs don't just grow out of separation anxiety

Now available in 90-count bottle sizes!



**Reconcile<sup>®</sup>**  
(fluoxetine hydrochloride)  
**Affordable. Reliable. Chewable.**

Flavored, chewable Reconcile<sup>®</sup> (fluoxetine hydrochloride) tablets, in conjunction with the BOND<sup>™</sup> training program, are clinically proven to help dogs that experience separation anxiety.



PRN and Reconcile are registered trademarks of Pegasus Laboratories, Inc.

**Important Safety Information:** The most common adverse events in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile<sup>®</sup> chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. Reconcile chewable tablets are indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

See page 29 for product information summary.

# Effect of Dietary Starch Sources on Canine Lipidemia

Camille Torres-Henderson, DVM, DABVP (Canine/Feline)  
Colorado State University

## In the literature

Teixeira FA, Machado DP, Jeremias JT, Queiroz MR, Pontieri CFF, Brunetto MA. Starch sources influence lipidaemia of diabetic dogs. *BMC Vet Res.* 2020;16(1):2.

## FROM THE PAGE ...

Hyperlipidemia is a disturbance of lipid metabolism that results in increased serum lipids (ie, triglycerides, cholesterol, or both). Hyperlipidemia in a fasted state is abnormal and indicates accelerated synthesis or reduced degradation of lipoproteins. Hyperlipidemia due to a lipid disorder is primary (ie, a defect of lipoprotein metabolism) or secondary (ie, characterized by increased lipoproteins, decreased lipoprotein catabolism, or both).

This randomized, crossover, double-blinded study evaluated the effects of 3 high-starch diets (ie, dietary peas/barley, peas/barley/rice, corn) in 12 dogs with stable diabetes and a history of hyperlipidemia. Dogs were fed a basal diet (9% fat on a dry-matter basis) for 60 days, then randomized to be fed each of the test diets for 60 days. The test diets had similar percentages of crude protein, fat, fiber, and ash but differed in sources of starch (ie, peas and barley vs corn). At the end of the test period, plasma triglyceride and cholesterol curves were measured over 10 hours.

Mean plasma triglyceride levels were significantly lower after the pea and barley diet trial as compared with the basal diet trial at fasting and 8 hours postprandial and as compared with the corn diet trial 4 hours postprandial. Mean, minimum, and maximum plasma cholesterol levels were significantly lower after the pea and barley diet as compared with the corn diet at all time points except during fasting; there were no differences as compared with the basal diet.

Feeding a lower-fat diet is considered critical for hyperlipidemia management. The results of this study suggest that dietary ingredients may also play an important role. Although dogs fed the pea and barley diet had lower cholesterol at several time points as compared with dogs fed the

**Pea protein has been found to reduce triglyceride and cholesterol levels in some species.**<sup>4-8</sup>

corn diet, hypercholesterolemia in dogs is believed to be less clinically important than hypertriglyceridemia. In addition, a complete dietary analysis of the diets was not specified, making it challenging to interpret the results. Barley contains beta-glucans (ie, polysaccharides found in the bran of cereal grains that have several reported health benefits in humans<sup>1,2</sup>) and has been evaluated in humans for its cholesterol- and lipid-lowering effects.<sup>3</sup> Pea protein has been found to reduce triglyceride and cholesterol levels in some species.<sup>4-8</sup> Although the mechanism is not fully understood, the benefit of pea protein may be due to increased hepatic activity of low-density lipoproteins, resulting in increased clearance of low-density lipoprotein cholesterol, decreased synthesis of fatty acids, and increased excretion of bile acids in feces.<sup>4-7</sup>

## ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Hyperlipidemia in a fasted dog or cat is abnormal and should be managed.
- 2** Dietary and drug interventions can decrease the morbidity associated with hyperlipidemia.
- 3** Dietary ingredients, fiber, and several nutrients (eg, beta-glucans), in addition to reduced dietary fat, may play an important role in management of patients with hyperlipidemia.

## References

1. Talati R, Baker WL, Pablonia MS, White CM, Coleman CI. The effects of barley-derived soluble fiber on serum lipids. *Ann Fam Med*. 2009;7(2):157-163.
2. Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P, Andersson H. Oat  $\beta$ -glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. *Am J Clin Nutr*. 1995;62(6):1245-1251.
3. Sima P, Vannucci L, Vetvicka V.  $\beta$ -glucans and cholesterol (review). *Int J Mol Med*. 2018;41(4):1799-1808.
4. Skottová N, Krecman V, Walterová D, Ulrichová J, Kosina P, Šimánek V. Effect of silymarin on serum cholesterol levels in rats. *Acta Univ Palacki Olomuc Fac Med*. 1998;141:87-89.
5. Rigamonti E, Parolini C, Marchesi M, et al. Hypolipidemic effect of dietary pea proteins: impact on genes regulating hepatic lipid metabolism. *Mol Nutr Food Res*. 2010;54(Suppl 1):S24-30.
6. Spielmann J, Stangl GI, Eder K. Dietary pea protein stimulates bile acid excretion and lowers hepatic cholesterol concentration in rats. *J Anim Physiol Anim Nutr (Berl)*. 2008;92(6):683-693.
7. Martins JM, Riottot M, de Abreu MC, et al. Dietary raw peas (*Pisum sativum* L.) reduce plasma total and LDL cholesterol and hepatic esterified cholesterol in intact and ileorectal anastomosed pigs fed cholesterol-rich diets. *J Nutr*. 134(12):3305-3312.
8. Dubois C, Cara L, Armand M, et al. Effects of pea and soybean fibre on postprandial lipaemia and lipoproteins in healthy adults. *Eur J Clin Nutr*. 1993;47(7):508-520.

# Osurnia<sup>®</sup>

(florfenicol, terbinafine, betamethasone acetate)

## Otic gel

### For Otic Use in Dogs Only

#### Do not use in cats

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

#### BRIEF SUMMARY (for full prescribing information, see package insert)

**DESCRIPTION:** OSURNIA contains 10 mg florfenicol, 10 mg terbinafine and 1 mg betamethasone acetate per mL and the inactive ingredients propylene carbonate, glycerol formal, hypromellose, phospholipid, oleic acid and BHT in an off-white to slightly yellow translucent gel.

**INDICATION:** OSURNIA is indicated for the treatment of otitis externa in dogs associated with susceptible strains of bacteria (*Staphylococcus pseudintermedius*) and yeast (*Malassezia pachydermatis*).

**DOSE AND ADMINISTRATION:** OSURNIA should be administered in the clinic. Clean and dry the external ear canal before administering the initial dose of the product. Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days. Do not clean the ear canal for 45 days after the initial administration to allow contact of the gel with the ear canal. Cleaning the ear may affect product effectiveness (see **Effectiveness** in the product insert). If alternative otic therapies are required it is recommended to clean the ear(s) before application. Open tube by twisting the soft tip. Insert the flexible tip into the affected external ear canal(s) and squeeze entire tube contents into the external ear canal(s). After application, gently massage the base of the ear to allow the gel to penetrate to the lower part of the ear canal.

**CONTRAINDICATIONS:** Do not use in dogs with known tympanic perforation (see **Precautions** in the product insert). Do not use in dogs with a hypersensitivity to florfenicol, terbinafine, or corticosteroids.

#### WARNINGS:

##### Human Safety Warning:

#### OSURNIA may cause eye injury and irritation

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. In case of accidental skin contact, wash area thoroughly with water.

**Avoid contact to the eyes. In case of accidental eye contact, flush thoroughly with water for at least 15 minutes. If symptoms develop, seek medical advice.**

#### PRECAUTIONS: Wear eye protection when administering OSURNIA and restrain the dog to minimize post-application head shaking.

Reducing the potential for splatter of product will help prevent accidental eye exposure in people and dogs and help to prevent ocular injury. Do not administer orally. The use of OSURNIA in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering this product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **Animal Safety** in the product insert). Use with caution in dogs with impaired hepatic function (see **Animal Safety and Adverse Reactions** in the product insert). The safe use of OSURNIA in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.

**ADVERSE REACTIONS:** The following adverse reactions were reported during the course of a US field study for treatment of otitis externa in dogs treated with OSURNIA in decreasing order: elevated liver enzymes, vomiting, weight loss (>10% body weight) and hearing loss. To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra Veterinary Products at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

**POST-APPROVAL EXPERIENCE (2020):** The following adverse events are based on post-approval adverse drug experience reporting for OSURNIA. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using this data.

**In humans,** accidental exposure leading to corneal ulcers and other ocular injuries such as eye irritation, burning, stinging, and itchiness have been reported to occur when the dog shook its head after application of OSURNIA.

**In dogs,** the adverse events reported for OSURNIA are presented below in decreasing order of reporting frequency: Deafness, ear discharge, ear irritation and pain, vomiting, head shaking, head tilt, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, nystagmus, tympanic rupture, and facial paralysis.

**INFORMATION FOR DOG OWNERS:** Owners should be aware that adverse reactions may occur following administration of OSURNIA and should observe dog for signs such as deafness, ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge (see **Animal Safety and Post-Approval Experience** in the product insert). Owners should be advised to contact their veterinarian if any of the above signs are observed.

Owners should also be informed that splatter may occur if the dog shakes its head following administration of OSURNIA which may lead to ocular exposure. As a result, eye injuries in humans and dogs have been reported including corneal ulcers.

**EFFECTIVENESS:** Effectiveness was evaluated in 235 dogs with otitis externa. The study was a double-masked field study with a placebo control (vehicle without the active ingredients). One hundred and fifty-nine dogs were treated with OSURNIA and seventy-six dogs were treated with the placebo control. All dogs were evaluated for safety. Treatment (1 mL) was administered to the affected ear(s) and repeated 7 days later. Prior to the first administration, the ear(s) were cleaned with saline but not prior to the Day 7 administration. Six clinical signs associated with otitis externa were evaluated: pain, erythema, exudate, swelling, odor and ulceration. Total clinical scores were assigned for a dog based on the severity of each clinical sign on Days 0, 7, 14, 30 and 45. Success was determined by clinical improvement at Day 45. The success rates of the two groups were significantly different ( $p=0.0094$ ); 64.78% of dogs administered OSURNIA were successfully treated, compared to 43.42% of the dogs in the placebo control group.

**STORAGE CONDITIONS:** OSURNIA should be stored under refrigerated conditions between 36° - 46° F (2° - 8° C). To facilitate comfort during administration, OSURNIA may be brought to room temperature and stored for up to three months.

#### MANUFACTURED FOR:

Dechra Veterinary Products  
7015 College Boulevard, Suite 525  
Overland Park, KS 66211 USA

Product of Great Britain

Approved by FDA under NADA # 141-437

OSURNIA<sup>®</sup> is a trademark of Dechra Ltd.  
All rights reserved.

R 03 2021





# Two reasons to recheck.



**Canine otitis externa treatment is only successful when you're confident your treatment is working.** That's why the follow-up appointment is so important. Resolve the infection with 2-dose Osumnia, use the follow-up to monitor the response to treatment and trust the Dechra dermatology portfolio to help you manage the underlying problem. To order or schedule a lunch and learn, call your Dechra representative or call (866) 683-0660.

**Osumnia<sup>®</sup>**  
(florfenicol-terbinafine-betamethasone acetate)

**For Veterinary Technical Support, Contact Dechra Veterinary Products at:**  
866-933-2472 | [www.dechra-us.com](http://www.dechra-us.com) | [support@dechra.com](mailto:support@dechra.com)

### Important Safety Information

As with all drugs, side effects may occur. In field studies and post-approval experience the most common side effects reported were vomiting, increased liver enzymes and loss of hearing. Other signs reported were ear discharge, ear irritation and pain, vomiting, head shaking, head tilt, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, nystagmus, tympanic rupture, and facial paralysis.

Osumnia<sup>®</sup> should be administered by a veterinary professional. Do not use in dogs with known tympanic perforation or a hypersensitivity to florfenicol, terbinafine or corticosteroids. **Osumnia may cause eye injury and irritation. Wear eye protection when administering Osumnia and restrain the dog** to minimize post-application head shaking. **Do not use in cats.** Refer to the prescribing information for complete details or visit [www.dechra-us.com](http://www.dechra-us.com).



# A Comparison of Nalbuphine, Butorphanol, & Morphine in Dogs

Andrew K. Claude, DVM, DACVAA  
Michigan State University

**As compared with morphine, neither butorphanol nor nalbuphine have been shown to reduce the minimum alveolar concentration of inhalant anesthetics.<sup>6</sup>**

## In the literature

Gomes VH, Barbosa D, Motta AS, Corrêa CG, Moreno DJ, da Silva MF. Evaluation of nalbuphine, butorphanol and morphine in dogs during ovariohysterectomy and on early postoperative pain. *Vet Anaesth Analg*. 2020;47(6):803-809.

## FROM THE PAGE ...

Although other analgesic drugs have increased in popularity, opioids continue to be extensively used for pre-, intra-, and postoperative analgesic periods in veterinary medicine.<sup>1</sup> Opioid analgesic drugs are classified according to the opioid receptor(s) at which they exert agonistic action.<sup>2</sup> Mu-opioid analgesic drugs include morphine, hydromorphone, methadone, and fentanyl; buprenorphine is classified as a partial mu agonist. Mixed agonist/antagonist drugs include butorphanol and nalbuphine; these are kappa agonists and predominately mu antagonists.

Morphine and butorphanol are commonly used in veterinary practice, but nalbuphine (a non-controlled, human opioid drug<sup>3</sup>) is not. Butorphanol and nalbuphine have similar pharmacologic and adverse effects in dogs and cats. However, there is conflicting evidence as to whether nalbuphine has equal or greater sedative and analgesic effects as compared with butorphanol or morphine, and extensive analgesic studies involving nalbuphine in veterinary medicine are lacking.<sup>4</sup> Butorphanol as an analgesic in small animals is less effective than mu agonists, partial mu agonists, and NSAIDs, primarily because of its short duration of action and ability to control only mild to moderate degrees of pain.<sup>5</sup> As compared with morphine, neither butorphanol nor nalbuphine have been shown to reduce the minimum alveolar concentration of inhalant anesthetics.<sup>6</sup> In addition, butorphanol should be used judiciously in patients with the multidrug sensitivity gene (*MDR1* gene, also known as *ABC1* gene).<sup>7</sup>

Continues ▶

# CHANGE THEIR BODY. CHANGE THEIR DIET.

## Neutering Is a Significant Major Risk Factor for Obesity in Dogs and Cats:<sup>1</sup>

- Reduced Caloric Need
- Increased Appetite
- Decreased Metabolism

## Pick a Diet Designed to Specifically Address These Changes

- High Protein
- High Fiber
- Balanced Caloric Density
- Formulas for Growth & Adulthood



To learn more about VETERINARY HPM<sup>®</sup> Spay & Neuter Diets, contact your Virbac representative or visit <https://vet-us.virbac.com/hpm>.

**VETERINARY  
HPM<sup>®</sup>** TAILORED NUTRITION FOR  
SPAYED & NEUTERED PETS



<sup>1</sup> Cline MG, Burns KM, Coe JB, et al. 2021 AAHA nutrition and weight management guidelines for dogs and cats. *J Am Anim Hosp Assoc.* 2021;57(4):153-178. doi: 10.5326/JAAHA-MS-7232.

This study compared the analgesic effects of intra- and postoperative nalbuphine (either 0.5 mg/kg or 1 mg/kg), butorphanol, and morphine administered with acepromazine for premedication in dogs undergoing ovariohysterectomy. The authors believed that morphine would provide the most effective analgesia as compared with nalbuphine and butorphanol and that nalbuphine would provide a dose-dependent degree of analgesia. The number of rescue doses of propofol needed to maintain an adequate level of anesthesia was used to assess intraoperative analgesia. The dynamic and interactive visual analog scale and the modified Glasgow composite measure pain scale were used to assess postoperative pain. No difference in the degree of analgesia was observed among the 3 opioids, and the effects of a higher and lower dose of nalbuphine were similar. All 3 opioids, when combined with acepromazine, provided insufficient analgesia for all dogs during the surgical procedure. In addition, none of the 4 premedication protocols provided acceptable analgesia within the first 6 hours postoperatively. The authors speculated that the morphine dose (0.2 mg/kg IV) may have been insufficient to provide adequate analgesia; however, the butorphanol and nalbuphine doses were comparable with those in other studies.

## Increasing the dose of nalbuphine or butorphanol may not provide increased analgesia because of their ceiling effects.

### ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** This study did not fully illustrate the antinociceptive advantages of morphine, butorphanol, and nalbuphine. However, opioid drugs are valuable analgesics for surgical procedures and should be administered pre-emptively to help control surgical nociception.
- 2** Increasing the dose of nalbuphine or butorphanol may not provide increased analgesia because of their ceiling effects. Increasing the dose of morphine (0.4-0.5 mg/kg) can increase analgesia but may also increase adverse effects. Mu-agonist opioids (eg, morphine, hydromorphone) or partial mu-agonist opioids (eg, buprenorphine) may provide better analgesia for surgical patients as compared with butorphanol or nalbuphine.
- 3** Administering maropitant prior to mu-agonist opioid drugs can decrease the incidence of vomiting in dogs and may provide additional analgesia.<sup>8,9</sup>
- 4** Butorphanol and nalbuphine are kappa agonists and mu antagonists; therefore, either can be used as a nonemergent, mu-opioid-reversing drug.

### References

1. Hellyer PW, Robertson SA, Fails AD, et al. Pain physiology, pharmacology, and management. In: Grimm KA, Tranquilli WJ, Lamont LA, eds. *Essentials of Small Animal Anesthesia and Analgesia*. 2nd ed. Wiley-Blackwell; 2011:82-146.
2. KuKanich B, Papich MG. Opioid analgesic drugs. In: Riviere JE, Papich MG, eds. *Veterinary Pharmacology and Therapeutics*. 9th ed. Wiley-Blackwell; 2009:301-334.
3. Narver HL. Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice. *Lab Anim (NY)*. 2015;44(3):106-110.
4. KuKanich B, Wiese AJ. Opioids. In: Grimm KA, Lamont LA, Tranquilli WJ, Greene SA, Robertson SA, eds. *Veterinary Anesthesia and Analgesia: The Fifth Edition of Lumb and Jones*. Wiley-Blackwell; 2015:207-226.
5. Lascelles BD, Robertson SA. Use of thermal threshold response to evaluate the antinociceptive effects of butorphanol in cats. *Am J Vet Res*. 2004;65(8):1085-1089.
6. Murphy MR, Hug CC Jr. The enflurane sparing effect of morphine, butorphanol, and nalbuphine. *Anesthesiology*. 1982;57(6):489-492.
7. Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. *J Vet Intern Med*. 2015;29(1):1-6.
8. Claude AK, Dedeaux A, Chiavaccini L, Hinz S. Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs. *J Vet Intern Med*. 2014;28(5):1414-1417.
9. Swallow A, Rioja E, Elmer T, Dugdale A. The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial. *Vet Anaesth Analg*. 2017;44(4):785-793.

# A DIFFERENT WAY TO CE



UP TO 14  
CE CREDITS



MINISTRY  
THROUGH THE  
PROFESSION  
TRACK



OVER 50  
SESSIONS



BREAKFAST,  
LUNCH, &  
DINNER  
INCLUDED



LIVE  
ENTERTAINMENT



**CVM  
Veterinary  
Conference**

Join us for a unique experience connecting veterinary professionals with opportunities for worship and fellowship, along with education and faith-based sessions!

**REGISTER NOW AT [WWW.CVMCEC.ORG](http://WWW.CVMCEC.ORG)**

**NOVEMBER 10-12, 2022 NASHVILLE, TN  
GAYLORD RESORT AND CONVENTION CENTER**

SPONSORED BY:  
**nutramax**<sup>®</sup>  
LABORATORIES  
VETERINARY SCIENCES, INC.

# Potential Tool for Prognosticating in Canine Mammary Gland Tumors

**Cheryl Balkman, DVM, MS, DACVIM (Internal Medicine, Oncology)**  
*Cornell University*

## In the literature

Ariyaratna H, Thomson NA, Aberdeen D, Perrott MR, Munday JS. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumors. *Vet Immunol Immunopathol.* 2020;230:110142.

## FROM THE PAGE ...

Immunosurveillance helps identify infected or abnormal cells. Signaling molecules, collectively referred to as *immune checkpoint molecules*, on T lymphocytes help regulate immunosurveillance and can be either activating or inhibitory. Inhibitory immune checkpoint molecules, which suppress T-lymphocyte activation, are aberrantly expressed in many human cancers. Suppression may allow tumors to evade the host immune surveillance, allowing more aggressive clinical behavior.

Two inhibitory immune checkpoint molecules often expressed in human tumors are programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4)<sup>1,2</sup>; these molecules are associated with more aggressive behavior and worse prognosis, and measuring their expression on tumors may help provide a more accurate prognosis.<sup>3,4</sup> A variety of canine tumors express PD-L1 and CTLA-4, which have been shown to be prognostic in canine high-grade B-cell lymphoma.<sup>5</sup> PDL-1 is detected more frequently in malignant than benign mammary gland tumors,<sup>6,7</sup> but association with prognosis has not been reported.

This study investigated the immunostaining and gene expression of PDL-1 and CTLA-4 in 41 histologically malignant and 12 benign canine mammary gland tumors with known outcomes. The goal was to determine whether PDL-1 and CTLA-4 immunostaining and gene expression are correlated with biological behavior and clinical outcome. Metastasized malignant mammary gland tumors had significantly higher immunostaining scores and gene expression for both PDL-1 and CTLA-4 than nonmetastasized malignant tumors.

On multivariate analysis, PDL-1 and tumor grade were independent prognostic indicators of survival; CTLA-4, tumor size, and tumor emboli were not independent prognostic indicators of survival.

## ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Canine malignant mammary gland tumors are a heterogeneous group of tumors with biological behavior that can be difficult to predict.
- 2** Different prognostic factors, including histologic subtype, tumor grade, and stage, have been evaluated, but additional factors likely play a role in the aggressive behavior of a tumor.
- 3** Results of this study show PDL-1 and CTLA-4 immunostaining of mammary gland tumors may allow better prognostication in dogs and could lead to development of future therapeutics.

## References

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol.* 2008;26:677-704.
2. Wülfing C, Tunbridge HN, Wraith DC. New inhibitory signaling by CTLA-4. *Nat Immunol.* 2014; 15(5):408-409.
3. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. *Cancer Immunol Immunother.* 2007;56(8):1173-1182.
4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell.* 2015;27(4):450-461.
5. Aresu L, Ferrareso S, Marconato L, et al. New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease. *Blood.* 2018;132(Suppl 1):4173.
6. Maekawa N, Konnai S, Okagawa T, et al. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. *PLoS One.* 2016;11(6):e0157176.
7. Shosu K, Sakurai M, Inoue K, et al. Programmed cancer cell death ligand 1 expression in canine cancer. *In Vivo.* 2016;30(3):195-204.

## Suggested Reading

- Canadas A, França M, Pereira C, et al. Canine mammary tumors: comparison of classification and grading methods in a survival study. *Vet Pathol.* 2019;56(2):208-219.
- Matos AJ, Baptista CS, Gärtner MF, Rutteman GR. Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. *Vet J.* 2012;193(1):24-31.
- Rasotto R, Berlato D, Goldschmidt MH, Zappulli V. Prognostic significance of canine mammary tumor histologic subtypes: an observational cohort study of 229 cases. *Vet Pathol.* 2017;54(4):571-578.



## THE EPICUR OATH

### Safer, consistent medications.

- Traditionally compounded medications available from a 503B Manufacturer overseen by the FDA
- Drugs manufactured following cGMP, the same regulations used by pharmaceutical companies
- Approved for distribution
- One of the largest portfolios of 503B drugs for animal health

**For a list of drugs, visit [epicurpharma.com](http://epicurpharma.com)  
888.508.5032**





# RESCUE YOUR PRACTICE TODAY.

We know your practice is focused on providing the best care to your patients so maintaining the highest standard of disinfection is crucial. It's time to choose a disinfectant that safeguards your practice and protects you, your staff and your patients from harmful pathogens.

**Choose Rescue™ today instead of wishing you had later.**

**RescueDisinfectants.com**

**RESCUE**® | Prevention Redefined



Warning: You must read and follow the instructions on the label for our product and use the product for the particular applications specified on the product label. To the full extent permitted under applicable law, Virox Technologies Inc. shall not be liable for any damages whatsoever, arising out of or otherwise in connection with any failure to follow those instructions or any use of its products which is not specified on the product's label. The instructions on the product label are not a warranty, express or implied, and Virox Technologies, Inc. expressly disclaims any implied warranties, including any warranty of fitness for a particular purpose. Under applicable law, some of the above waivers or disclaimers of warranty, or exclusions of liability for certain types of damages may not apply to you. In such cases, our liability will be limited to the fullest extent permitted by applicable law.

# Screening Liver & Kidney Values Prior to NSAIDs

---

Faith I. Buckley, DVM, DACVIM (SAIM)

Mobile Veterinary Specialists (MOVES)

Londonderry, New Hampshire


## In the literature

Chalifoux NV, Kaiman G, Drobatz KJ, Thawley VJ. Evaluation of renal and hepatic blood value screening before non-steroidal anti-inflammatory drug administration in dogs. *J Small Anim Pract.* 2021;62(1):12-18.

---

## FROM THE PAGE ...

NSAIDs are commonly prescribed in veterinary medicine, but there are concerns regarding safety profiles of these drugs.<sup>1-3</sup> Reported adverse effects include anorexia; lethargy; vomiting; gastric irritation, ulceration, and perforation; renal insufficiency; and idiosyncratic hepatotoxicity.



---

**Dogs with elevated hepatic blood values were less likely to have an NSAID administered, although this was not the case for an elevated renal parameter in isolation.**

Continues ►

In this retrospective study, medical records of 81 dogs with laboratory evaluations conducted in advance of NSAID therapy were reviewed. Of these, 56% had an elevation in at least one renal (ie, BUN, creatinine) or hepatic (ie, ALP, ALT, AST) value; these values are often reflective of renal perfusion, hepatocellular injury, and cholestasis.

Dogs with elevated hepatic blood values were less likely to have an NSAID administered, although this was not the case for an elevated renal parameter in isolation. This variation in administration may be due to the relatively low number of dogs with an elevated renal parameter, as opposed to a lack of concern for renal elevation. Results also suggested that dogs <8 years of age were less likely to have an elevated renal or hepatic blood value, questioning screening utility in young, healthy, euvolemic patients. Other associations pertaining to patient history, physical examination, or onset of illness were not significant.

### ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Patients with compromised circulating volume (eg, dehydration, hypotension, GI losses, ascites, congestive heart failure) are at increased risk for adverse effects secondary to NSAID administration.
- 2** Although risk factors for idiosyncratic, life-threatening hepatotoxicity are unknown, there is concern that NSAID administration may exacerbate pre-existing underlying hepatitis.<sup>4</sup>
- 3** Regardless of physical examination and serum chemistry profile findings, pet owners should be informed of the possible adverse effects prior to an NSAID being administered and guided to seek medical care if adverse effects occur.

### References

1. Lascelles BD, McFarland JM, Swann H. Guidelines for safe and effective use of NSAIDs in dogs. *Vet Ther*. 2005;6(3):237-251.
2. KuKanich B, Bidgood T, Knesl O. Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. *Vet Anaesth Analg*. 2012;39(1):69-90.
3. Lawson A, Walton B. Monitoring side effects of long-term NSAID use in dogs with chronic osteoarthritis. *In Pract*. 2019;41(4):148-154.
4. MacPhail CM, Lappin MR, Meyer DJ, Smith SG, Webster CR, Armstrong PJ. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. *J Am Vet Med Assoc*. 1998;212(12):1895-1901.

## Research Note: Transmittable Blood-Borne Disease from Canine Blood Donors

This registry-based retrospective study examined 6,150 units of blood from 1,914 active canine blood donors in order to estimate and predict positivity of transmittable blood-borne pathogens. Of the 1,779 units tested for antibodies, 10 (0.56%) were positive for antibodies against *Anaplasma phagocytophilum* and *A platys*, and none had antibodies against *Ehrlichia canis* or *Ewingii*. After excluding the antibody-positive units, 1.1% of 6,140 units were found to be PCR-positive for *A phagocytophilum*, *Bartonella* spp, *Brucella canis*, *Candidatus Mycoplasma haematoparvum*, *Mycoplasma haemocanis*, or a combination thereof. Units from the first blood collection were more likely to test PCR-positive for pathogens than were units from subsequent collections. The prevalence of transmittable pathogens is low but represents a risk to transfusion recipients, highlighting the importance of screening blood donors, especially those donating for the first time.

### Source

Nury C, Blais M-C, Arsenault J. Risk of transmittable blood-borne pathogens in blood units from blood donor dogs in Canada. *J Vet Intern Med*. 2021;35(3):1316-1324.

# *SLOW TO HEEL. FAST TO HEAL.*

## **DEEP, QUICK SKIN REPAIR.**

Even our furry friends with selective hearing can heal skin lesions twice as fast. With Phovia Fluorescent Light Therapy System.



# **PHOVIA**

An accelerated dermatology system.



**For more information, visit:**  
[www.vetoquinolusa.com/phovia](http://www.vetoquinolusa.com/phovia)

©2021 Vetoquinol USA, Inc. Vetoquinol, and the Vetoquinol logo, are registered trademarks of Vetoquinol USA, Inc. PHO-0535-PRAD21 12/21





ULTRASOUND SYSTEMS YOU HAVE TO SEE TO BELIEVE



**PILOTER**

Smart tablet system with CoreVu connectivity

- Portable for any environment
- Touch screen usage
- Five year warranty



**NAVI**

Precision imaging with CoreVu connectivity

- Nine hour battery
- 19" touchscreen
- Abdominal, POC, Cardiac Presets
- Five year warranty



CoreVu™

- + Embedded ultrasound consultation solution for:
  - Education
  - Support
  - Diagnostic Improvement
- + Access sonographers when you want, where you want
- + Guarantees you will be up and running on day one
- + Enhance scanning knowledge without leaving your practice



**INTEGRA**

**THE GOLD STANDARD IN POINT OF CARE ULTRASOUND**

The Integra ultrasound system works with any Android tablet or phone and features the highest quality micro-convex imaging in the marketplace!

- + An entire family of transducers for every need
- + Weighs less than ¼ pound
- + 3 year warranty
- + Unmatched imaging capabilities



# Greetings, Departures, & Canine Separation Anxiety

---

**Katherine A. Houpt, VMD, PhD**  
*Cornell University*

## In the literature

Teixeira AR, Hall NJ. Effect of greeting and departure interactions on the development of increased separation-related behaviors in newly adopted adult dogs. *J Vet Behav.* 2021;41:22-32.

---

## FROM THE PAGE ...

Separation anxiety is common in dogs, especially those adopted as adults. This study assessed whether high-arousal departures and greetings can lead to or be associated with separation anxiety. Many veterinary behaviorists suggest minimizing greetings and departures as part of a treatment plan for dogs with separation anxiety, as excessive greeting has been previously reported as a risk factor for separation anxiety.<sup>1</sup> The first half of this study compared the behavior of shelter dogs after a high-arousal situation (ie, being played with, petted, and spoken to) versus a low-arousal situation (ie, receiving a calm and brief greeting, receiving a short petting interaction, then being ignored) before being left alone in an unfamiliar room. Heart rate, activity, and vocalizations were measured across 10 trial sessions. Initially, the heart

---

**This study assessed whether high-arousal departures and greetings can lead to or be associated with separation anxiety.**



rate and activity were higher in dogs after a high-arousal situation, but values decreased across sessions. Of note, these dogs were in a relatively barren room (not a home) and had no prior relationship with the human who interacted with them; thus, this may not be a particularly good measure of separation anxiety.

The second half of this study involved a more clinically applicable experiment in which a questionnaire for dog owners was posted on multiple dog-related Facebook groups, including a group focused on separation anxiety. Owners were asked how they originally greeted and departed from their dog, whether this had changed over time, and, if changed, how they now greet and depart from their dog. Responses from owners of dogs with ( $n = 978$ ) and without ( $n = 1,012$ ) separation anxiety were compared. Owners of dogs with separation anxiety reported engaging in low-arousal greetings and departures both when they initially acquired the dog and presently. Owners scored their dogs for separation-anxiety-related behaviors (eg, barking, destructiveness); these scores were not correlated with the intensity of greetings or departures. The authors concluded that high-arousal greetings and departures were not risk factors for separation anxiety; however, further research—including video-recorded observation of newly adopted dogs when owners leave and return—is warranted.

### ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Separation anxiety may be more prevalent in dogs adopted after the sensitive period for socialization (7-16 weeks); owners of these dogs should be instructed to begin leaving their dog alone for short periods to habituate them to being alone.
- 2** Based on the results of this study, intensity of departures and greetings may not be correlated with separation anxiety, and it may not be necessary to advise owners to ignore their dog when leaving and returning home; however, further research is needed.

### Reference

1. Flannigan G, Dodman NH. Risk factors and behaviors associated with separation anxiety in dogs. *J Am Vet Med Assoc.* 2001;219(4):460-466.

### Suggested Reading

- Ogata N. Separation anxiety in dogs: what progress has been made in our understanding of the most common behavioral problems in dogs? *J Vet Behav.* 2016;16:28-35.
- Parthasarathy V, Crowell-Davis SL. Relationship between attachment to owners and separation anxiety in pet dogs (*Canis lupus familiaris*). *J Vet Behav.* 2006;1(3):109-120.
- Takeuchi Y, Houpt KA, Scarlett JM. Evaluation of treatments for separation anxiety in dogs. *J Am Vet Med Assoc.* 2000;217(3):342-345.

## Research Note: Efficacy of a Nonnucleoside Inhibitor Against FIP Virus

Prevention and treatment options for FIP, a virulent pathotype of feline enteric coronavirus, are limited. Feline recombinant interferon omega is the most commonly available antiviral treatment, but its efficacy against FIP virus has not been well-demonstrated. ERDRP-0519 (ERDRP), a nonnucleoside inhibitor that targets RNA polymerase, is effective against in vitro and in vivo morbilliviruses. This study examined the in vitro efficacy of ERDRP against FIP virus. Results demonstrated significant inhibition of FIP virus replication in a dose-dependent manner, confirming ERDRP is highly effective against a coronavirus in vitro. Further study is needed to assess suitability of ERDRP in treatment of FIP virus in vivo.

### Source

Camero M, Lanave G, Catella C, et al. ERDRP-0519 inhibits feline coronavirus in vitro. *BMC Vet Res.* 2022;18(1):55.



# SEAMLESS SUPPORT THROUGH THE GO, GO, GO OF DAILY PRACTICE

Plumb's Pro is built for busy veterinarians just like you.



Your practice requires fast, powerful clinical support at the point of care. Get the essential clinical information and practical tools you need for every step of patient care—right when you need them.



Scan the code and watch a demo of Plumb's Pro.

# TAKING ON TOUGH QUESTIONS



AMERICAN  
HEARTWORM  
SOCIETY™  
EST. 1974

FAQs ABOUT HEARTWORM DIAGNOSIS, PREVENTION AND MANAGEMENT

**Q** Dear AHS: At the 30-day recheck following heartworm adulticide treatment, my client's dog is still positive for microfilaria. Why is the dog still positive and what should I do? – Dr. M.



**TOM NELSON, DVM**  
Medical Director,  
Animal Medical Centers  
of N.E. Alabama

## THE SHORT ANSWER

If the dog was treated with the full AHS protocol and is on heartworm prevention, there is little cause for concern.

As part of its heartworm treatment protocol, the AHS recommends that dogs that have undergone melarsomine treatment for heartworms be rechecked for microfilaria (MF) 30 days after their last injection, which is Day 120 following diagnosis. If you're seeing MF on Day 120, consider these questions:

**Which heartworm preventive did you give during the pretreatment phase?** The AHS protocol recommends administering an "appropriate heartworm preventive" on Days 1 and 30 as part of the pretreatment protocol that also includes doxycycline and either ivermectin or moxidectin. These macrocyclic lactones coupled with doxycycline suppress embryogenesis, weaken adult heartworms, and have adulticidal activity.

**Did you give the full dose of doxycycline?** Doxycycline is administered to eliminate the *Wolbachia* bacteria prior to giving melarsomine. *Wolbachia* are necessary for embryogenesis and giving 4 weeks of doxycycline at 10 mg/kg B.I.D. should result in amicrofilaremia for at least 12 months. If you dose doxycycline properly, any residual MF won't develop into adult worms;

however, if you gave doxycycline at a lower dose (e.g., 5 mg/kg) or shorter time period, the *Wolbachia* could recrudescence and embryogenesis may have not been completely suppressed.


### Was the full dose of melarsomine given?

Melarsomine is an adulticide, but it does not kill microfilaria—nor is it absolutely 100% effective. However, if you give melarsomine as part of a 3-dose protocol, you will kill 98% of the worms, including 100% of male worms. Even if a female worm survived, it cannot produce microfilariae without a male worm. Giving the full recommended dose of melarsomine is essential as underdosing will affect efficacy! A bottle of melarsomine treats a 44-pound dog, so if the dog weighs 50 pounds, you will have to open a second vial. While melarsomine is a costly medication that must be used within 24 hours once opened, practitioners should avoid the temptation to underdose patients.

### Could it be a case of macrocyclic lactone-resistant heartworms?

While heartworm resistance isn't common, you should monitor for potentially resistant isolates in your practice area. When you do the Knott test, count the MF, then administer topical moxidectin which is the only FDA-approved microfilaricide. A week later, you can do another Knott test and once again do a count. If the number has dropped by half, chances are the heartworms weren't resistant. If the number hasn't dropped, you may be looking at a resistant isolate. While the presence of macrocyclic lactone-resistant isolates in your area is of concern, the good news is they are not resistant to melarsomine.

The most important factor with MF in a heartworm-positive dog is to prevent future heartworm transmission. If you follow the AHS treatment protocol diligently, any remaining MF will not pose a threat.



# Surgical Site Infection Following Extracapsular Cranial Cruciate Ligament Repair

**Jonathan Miller, DVM, MS, DACVS**  
Oradell Animal Hospital  
Paramus, New Jersey

## In the literature

Cox T, Maddox TW, Pettitt R, Wustefeld-Janssens B, Innes J, Comerford E. Investigation of variables associated with surgical site infection following the management of canine cranial cruciate ligament rupture with a lateral fabellotibial suture. *Vet Comp Orthop Traumatol.* 2020;33(6):409-416.

## FROM THE PAGE ...

Surgical site infection (SSI) is an important cause of morbidity in dogs. Previous studies based on older guidelines from the Centers for Disease Control and Prevention have reported SSI rates of <5% for the lateral fabellar nylon suture technique, a procedure used for cranial cruciate ligament (CCL) repair.<sup>1,2</sup>

This study examined SSI rates and contributing variables for lateral suture surgery of the stifle joint in dogs; 150 surgical procedures in 130 dogs were evaluated, and the SSI rate was found to be 17.3%. Of these, infected joints were found in 73.1% of dogs; 53% of affected dogs required implant removal. All infections were *Staphylococcus* spp, with only 10.5% of isolates being methicillin resistant. Although all dogs received perioperative beta-lactam antibiotics, only 13.3% received a postoperative antibiotic course. Postoperative antibiotics have been associated with reduced SSI in some CCL studies.<sup>3,4</sup>

Variables significantly associated with SSI included increased body weight and use of propofol instead of alfaxalone as an anesthetic induction agent. For each 2.2-lb (1-kg) increase in body weight, the SSI rate increased 4%. Use of propofol was associated with a 3.6-fold increase.

## ... TO YOUR PATIENTS

Key pearls to put into practice:

- 1** Heavier dogs have a higher risk for post-operative infection of the stifle joint after lateral fabellotibial nylon suture technique for CCL rupture.
- 2** Dogs receiving alfaxalone as an anesthetic induction agent for lateral fabellotibial nylon suture repair may have lower risk for SSI than when propofol is used.
- 3** If SSI occurs after extracapsular suture repair for CCL rupture, the lateral suture may need to be removed in ~50% of cases.

## References

1. Casale SA, McCarthy RJ. Complications associated with lateral fabellotibial suture surgery for cranial cruciate ligament injury in dogs: 363 cases (1997-2005). *J Am Vet Med Assoc.* 2009;234(2):229-235.
2. Frey TN, Hoelzler MG, Scavelli TD, Fulcher RP, Bastian RP. Risk factors for surgical site infection-inflammation in dogs undergoing surgery for rupture of the cranial cruciate ligament: 902 cases (2005-2006). *J Am Vet Med Assoc.* 2010;236(1):88-94.
3. Pratesi A, Moores AP, Downes C, Grierson J, Maddox TW. Efficacy of postoperative antimicrobial use for clean orthopedic implant surgery in dogs: a prospective randomized study in 100 consecutive cases. *Vet Surg.* 2015;44(5):653-660.
4. Spencer DD, Daye RM. A prospective, randomized, double-blinded, placebo-controlled clinical study on postoperative antibiotherapy in 150 arthroscopy-assisted tibial plateau leveling osteotomies in dogs. *Vet Surg.* 2018;47(8):E79-E87.

"TICK TOCK,  
TICK TOCK"

— YOUR NEXT APPOINTMENT



The *Clinician's Brief* Algorithm Collection helps you get to diagnosis and treatment with speed and certainty

Get clear, easy-to-follow management trees on everything from anemia and fractured teeth to cardiac arrhythmias and vestibular disease, so you can make confident decisions—even when the clock is ticking.

Order your collection at [cliniciansbrief.com/algorithms](http://cliniciansbrief.com/algorithms)

# Top 5 Signs of Patient Stress & Excitement on Clinical Pathology

R. Darren Wood, DVM, DVSc, DACVP  
(Clinical Pathology)  
University of Guelph  
Guelph, Ontario, Canada



Evaluation of laboratory data for indicators of underlying disease is a mainstay of veterinary diagnostics. In addition to disease mechanisms, routine physiologic responses can also impact measured variables. A common example of an interpretive consideration is patient stress and/or excitement due to illness or unfamiliarity with the veterinary clinic.

## TOP 5 SIGNS OF PATIENT STRESS & EXCITEMENT ON CLINICAL PATHOLOGY

1. Stress Leukogram
2. Physiologic Leukocytosis
3. Erythrocytosis
4. Hyperglycemia
5. Increased Corticosteroid-Induced ALP Activity

Following are the author's top 5 signs of patient stress and excitement on clinical pathology.

### 1 Stress Leukogram

A stress leukogram is a common set of leukocyte responses caused by the release of endogenous corticosteroids that result from stress-related disease and hospitalization. Possible changes include segmented neutrophilia, lymphopenia, monocytosis, and eosinopenia, but all abnormalities are not always present,<sup>1</sup> and it is unusual for alterations to vary >2 to 3 times the reference values.<sup>2</sup> Lymphopenia is most common, and segmented neutrophilia is usually present.<sup>3</sup> Monocytosis and eosinopenia are possible in dogs; however, they are more variable and frequently not present in cats.

Neutrophilia is caused by decreased adherence to the vascular endothelium from receptor downregulation, which inhibits margination of cells and therefore increases the proportion of cells in the circulating pool inside blood vessels.<sup>4</sup> Prolonged circulation time may

cause neutrophils to appear hypersegmented,<sup>5</sup> and increased release of neutrophils from bone marrow is possible.<sup>4</sup> The segmented neutrophil count can double in dogs and triple in cats due to a larger number of cells in the marginating pool.<sup>6</sup> Neither a left shift to band neutrophils or toxic changes are expected due to lack of inflammatory response.

Instead of entering circulation, lymphocytes become redistributed to and retained in lymphocytic tissue (eg, lymph nodes).<sup>6</sup> It is suspected that monocytes increase in concentration due to mechanisms similar to those of neutrophils (eg, decreased margination), although this has not been definitively proven. Eosinopenia can be difficult to detect because eosinophils are rare and only a few may be present in circulation at baseline.

The stress leukogram is transient, and cell dynamics return to normal when increased stress is resolved.<sup>3</sup> The changes observed in a stress leukogram can also occur with consistently increased cortisol concentrations in patients with hyperadrenocorticism. Stressed patients with underlying illness may have a co-occurring inflammatory leukogram as suggested by the presence of a left shift and neutrophil toxicity; these do not occur with a stress response alone.

---

**The stress leukogram is transient, and cell dynamics return to normal when increased stress is resolved.<sup>3</sup>**

## 2 Physiologic Leukocytosis

Leukocytosis can be caused by fear, exercise, or excitement; is mediated by increased catecholamine concentrations (eg, epinephrine, norepinephrine); and should be considered a transient physiologic response. Catecholamine hormones can cause cells from the marginating pool to shift to the circulating pool in the vasculature.<sup>5,7</sup> This effect may double the total WBC concentration within minutes but is temporary, and, at least in horses, cell counts return to baseline values after 30 minutes.<sup>8</sup> In addition, splenic contraction induced by catecholamine hormones can expel leukocytes into the peripheral circulation.

Leukocytosis is usually characterized by segmented neutrophilia without a left shift. Lymphocytosis may be present, especially in kittens and young cats. The effect in cats is often considered a prominent lymphocytosis, which can be up to twice the upper reference value.<sup>5,6</sup>

## 3 Erythrocytosis

Transient erythrocytosis occurs when catecholamines from excitement or stress cause splenic contraction, resulting in expulsion of stored erythrocytes into circulation.<sup>9</sup> Transient erythrocytosis is most common in young horses, less frequent in dogs, and unusual in cats—possibly because the feline spleen is nonsinusoidal—but can occur under experimental conditions.<sup>5,10</sup> RBC concentration (ie, hematocrit) only slightly increases in most small animals, and the effect may not be appreciated because values may remain within reference intervals. In a study, the hematocrit of racing greyhounds increased immediately posttrace, presumably due to catecholamine-induced splenic contraction, although decreased plasma volume may have also been a contributing factor.<sup>11</sup>

## 4 Hyperglycemia

Transient stress hyperglycemia, or physiologic hyperglycemia, is particularly common in cats and is most likely due to catecholamine release in acute cases, resulting in glycogenolysis and suppression of insulin release.<sup>12</sup> An increase in glucose and lactate concentrations has been correlated with epinephrine and norepinephrine, but not cortisol, concentrations.<sup>12</sup>

Stress hyperglycemia should be differentiated from diabetes mellitus, but this can be challenging, especially in cats, as blood glucose can become increased with stress alone. Diabetes mellitus is unlikely if repeat sampling for hyperglycemia is negative. In patients with chronic stress, endogenous corticosteroids may be more likely to cause hyperglycemia.<sup>13</sup> Catecholamines and corticosteroids can be contributing factors for transient hyperglycemia in hospitalized patients.

Measuring fructosamine concentration can also help discern stress-related hyperglycemia from diabetes mellitus.<sup>14</sup> In dogs, infusion of a combination of glucagon, epinephrine, and cortisol (ie, stress hormones) more effectively induced hyperglycemia than individual hormones.<sup>15</sup> Glucosuria may occur with stress-related hyperglycemia, particularly in cats, if the renal threshold is exceeded.

## 5 Increased Corticosteroid-Induced ALP Activity

Chronic stress in dogs can cause long-term increase of endogenous corticosteroids, which may result in increases in serum ALP activity. Increased activity is initially due to an increase in the liver ALP isoenzyme; corticosteroid-induced ALP (C-ALP) activity begins to increase after 7 days.<sup>16</sup> Evidence indicates that hepatocytes upregulate a gene that generates C-ALP when exposed to corticosteroids.<sup>17</sup> Cats do not have C-ALP.

Enzymatic activity may remain increased for several weeks after stress has resolved due to the prolonged half-life of the hormones. C-ALP activity can be used to screen for hyperadrenocorticism, but screening can be challenging in stressed patients. Although C-ALP can be measured specifically, only total ALP activity is typically reported. It is thus important to consider the impact of stress when investigating liver disease.<sup>18</sup>

### Conclusion

Patient stress and excitement may interfere with routine laboratory data interpretation. It is important to consider these factors so the most accurate conclusions are drawn and the patient is managed appropriately.

References on next page ▶

**Stress hyperglycemia should be differentiated from diabetes mellitus, but this can be challenging, especially in cats, as blood glucose can become increased with stress alone.**

C-ALP = corticosteroid-induced ALP

## References

1. Moore GE, Mahaffey EA, Hoenig M. Hematologic and serum biochemical effects of long-term administration of anti-inflammatory doses of prednisone in dogs. *Am J Vet Res.* 1992;53(6):1033-1037.
2. Lowe AD, Campbell KL, Barger A, Schaeffer DJ, Borst L. Clinical, clinicopathological and histological changes observed in 14 cats treated with glucocorticoids. *Vet Rec.* 2008;162(24):777-783.
3. Ekstrand C, Pettersson H, Gehring R, Hedeland M, Adolfsson S, Lilliehook I. Prednisolone in dogs—plasma exposure and white blood cell response. *Front Vet Sci.* 2021;8:666219.
4. Nakagawa M, Terashima T, D'yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. *Circulation.* 1998;98(21):2307-2313.
5. Stockham SL, Keeton KS, Szladovits B. Clinical assessment of leukocytosis: distinguishing leukocytoses caused by inflammatory, glucocorticoid, physiological, and leukemic disorders or conditions. *Vet Clin North Am Small Anim Pract.* 2003;33(6):1335-1357.
6. Valenciano AC, Decker LS, Cowell RL. Interpretation of feline leukocyte responses. In: Weiss DJ, Wardrop KJ, eds. *Schalm's Veterinary Hematology.* 6th ed. Blackwell Publishing; 2010:336.
7. Shultze AE. Interpretation of canine leukocyte responses. In: Weiss DJ, Wardrop KJ, eds. *Schalm's Veterinary Hematology.* 6th ed. Blackwell Publishing; 2010:321.
8. Rose RJ, Allen JR, Hodgson DR, Stewart JH, Chan W. Responses to submaximal exercise and training in the horse: changes in haematology, arterial blood gas and acid base measurements, plasma biochemical values and heart rate. *Vet Rec.* 1983;113(26-27):612-618.
9. Deniau V, Depecker M, Bizon-Mercier C, Courouge-Malblanc A. Influence of detomidine and xylazine on spleen dimensions and on splenic response to epinephrine infusion in healthy adult horses. *Vet Anaesth Analg.* 2013; 40(4):375-381.
10. Breznock EM, Strack D. Effects of the spleen, epinephrine, and splenectomy on determination of blood volume in cats. *Am J Vet Res.* 1982;43(11):2062-2066.
11. Horvath SJ, Couto CG, Yant K, et al. Effects of racing greyhounds on reticulocyte concentrations in greyhounds. *Vet Clin Pathol.* 2014; 43(1):15-23.
12. Rand JS, Kinnaird E, Baglioli A, Blackshaw J, Priest J. Acute stress hyperglycemia in cats is associated with struggling and increased concentrations of lactate and norepinephrine. *J Vet Intern Med.* 2002;16(2):123-132.
13. Stockham SL, Scott MA. Glucose, ketoamines and related regulatory hormones. In: Stockham SL, Scott MA. *Fundamentals of Veterinary Clinical Pathology.* 2nd ed. Blackwell Publishing; 2008:714.
14. Crenshaw KL, Peterson ME, Heeb LA, Moroff SD, Nichols R. Serum fructosamine concentration as an index of glycemia in cats with diabetes mellitus and stress hyperglycemia. *J Vet Intern Med.* 1996; 10(6):360-364.
15. Eigler N, Sacca L, Sherwin RS. Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia. *J Clin Invest.* 1979;63(1):114-123.
16. Solter PF, Hoffman WE, Chambers MD, Schaeffer DJ, Kuhlenschmidt MS. Hepatic total 3-alpha-hydroxy bile acids concentration and enzyme activities in prednisone-treated dogs. *Am J Vet Res.* 1994; 55(8):1086-1092.
17. Wiedmeyer CE, Solter PF, Hoffman WE. Kinetics of mRNA expression of alkaline phosphatase isoenzymes in hepatic tissues from glucocorticoid-treated dogs. *Am J Vet Res.* 2002;63(8):1089-1095.
18. Stockham SL, Scott MA. Enzymes. In: Stockham SL, Scott MA. *Fundamentals of Veterinary Clinical Pathology.* 2nd ed. Blackwell Publishing; 2008:656.



**BEFORE** **AFTER**

VETIGEL helps control bleeding in animals by achieving hemostasis in seconds. For additional information, refer to Instructions for Use.

Get 25% off your first order Use code 25off1 at checkout store.vetigel.com




### LOOK FOR THESE ARTICLES IN FUTURE ISSUES

- Metatarsal Draining Tract in a German Shepherd Dog
- Incisional Biopsy of Oral Tumors
- Acute Gastroenteritis in Dogs
- Top 5 Ocular Consequences of Systemic Hypertension
- Chronic Diarrhea in a Dog
- Incisional Biopsy of Subcutaneous Tumors

# Eyelid Mass with Conjunctival & Periocular Swelling in a Cat

Sarah Bosch, DVM  
Susan Nelson, DVM  
Jessica Meekins, DVM, MS, DACVO  
Lisa M. Pohlman, DVM, MS, DACVP  
Kansas State University



▲ **FIGURE 1** The entire upper eyelid and periocular skin around the medial canthus and extending to the medial lower eyelid associated with the left eye are moderately to severely and diffusely thickened and alopecic. Image courtesy of Guinevere Rava (veterinary student and Belinda's foster caretaker)

## Clinical History & Signalment

Belinda, a 9-lb (4-kg), 5-year-old spayed domestic shorthair cat, was returned to an animal shelter approximately one year after adoption with a recurring mass on the upper left eyelid (*Figure 1*). The conjunctiva and periocular tissue around the left eye were thickened and inflamed; periocular alopecia was also present. Belinda had been acting normally at home, and the surrendering owner had no other concerns.

An incisional biopsy of the mass had been performed one year prior, and a cutaneous mast cell tumor (MCT) was diagnosed; at the time, histopathology showed the mast cells extended to the surgical margins, which is expected with incisional biopsy, and no mitotic figures were seen.

## Physical Examination

On physical examination, Belinda was bright, alert, and responsive. Her vital parameters were within

normal limits. The entire upper left eyelid and periocular skin around the medial canthus and extending to the medial lower eyelid exhibited moderate to severe diffuse thickening and alopecia. The left mandibular lymph node was mildly enlarged. The remainder of the physical examination was within normal limits.


## Diagnostics

There were no significant abnormalities on CBC and serum chemistry profile. Premedication with diphenhydramine (2 mg/kg IM) was administered prior to fine-needle aspiration of the mass and mandibular lymph node. Cytology of the mass was highly cellular and composed predominantly of variably granulated mast cells (*Figure 2*, next page). There was mild to moderate anisocytosis and mild anisokaryosis. Binucleated cells were frequent.


MCT = mast cell tumor

Left mandibular lymph node aspirate showed frequent, well-granulated mast cells distributed individually and in groups among a population of lymphocytes, including predominantly small lymphocytes with fewer medium and large lymphocytes and scattered plasma cells (Figures 3 and 4). Given the cytologic findings from the mass and


lymph node, abdominal ultrasonography was performed. No abnormalities were seen on ultrasound, but a fine-needle aspirate of the spleen revealed an increased concentration of mast cells scattered individually and in small groups among normal splenic lymphoid and hematopoietic tissue (Figure 5).




▲ **FIGURE 2** Fine-needle aspirate of the subcutaneous, periorbital mass showing a sample composed predominantly of variably granulated mast cells. Well-granulated (**solid arrows**) and poorly granulated (**circles**) mast cells can be seen. Eosinophils (**arrowheads**), macrophages (**asterisk**), and occasional lymphocytes (**curved arrow**) and spindle cells (**dashed arrow**) consistent with reactive fibroblasts are also present. No mitotic figures were identified. *Modified Wright's stain, 1,000× magnification*



▲ **FIGURE 4** Fine-needle aspirate of the left mandibular lymph node showing abundant lymphocytes (consistent with a lymph node aspirate) with frequent, well-granulated mast cells (**arrows**). Large, round-to-oval clear spaces (**asterisks**) represent lipid droplets removed from the smear upon staining. *Modified Wright's stain, 1000× magnification*



▲ **FIGURE 3** Fine-needle aspirate of the left mandibular lymph node showing abundant, predominantly small lymphocytes with frequent, well-granulated mast cells (**arrows**; not all mast cells are indicated). Large, round to oval clear spaces (**asterisks**) represent lipid droplets removed from the smear upon staining. Boxed area is shown in **Figure 4**. *Modified Wright's stain, 600× magnification*



▲ **FIGURE 5** Splenic aspirate showing well-granulated mast cells (**solid arrows**) that exhibit mild anisocytosis. RBCs; frequent unidentifiable ruptured cells (**dashed arrows**), often referred to as *smudge cells* because only smudged nuclear material remains; platelet clumps (**circles**); and an eosinophil (**arrowhead**) can also be seen. *Modified Wright's stain, 1,000× magnification*

MCT = mast cell tumor

## DIAGNOSIS:

### FELINE CUTANEOUS MAST CELL TUMOR WITH REGIONAL LYMPH NODE & SPLENIC METASTASIS

#### Treatment

Surgery was not pursued because of the presence of metastatic disease. Belinda was placed in palliative care in a permanent foster home. She was prescribed diphenhydramine (12.5 mg PO every 12 hours), famotidine (10 mg PO every 24 hours), and prednisolone (7.5 mg PO every 24 hours). Periodic attempts were made to decrease the prednisolone dose; however, increased swelling, erythema, and pruritus with self-injury were consistently noted, and the initial prescribed dose (7.5 mg PO every 24 hours) was determined to be the appropriate maintenance dose.

#### Prognosis & Outcome

Belinda continued to do well for 15 months, at which time she was returned for evaluation of moderate, focal, cranial abdominal pain with apparent nausea and vomiting. She weighed 9.72 lb (4.41 kg). CBC and serum chemistry profile were unremarkable, and imaging was considered but declined. Maropitant (4.4 mg SC every 24 hours for 3 days), lactated Ringer's solution (100 mL SC), and buprenorphine (0.044 mg via buccal oral transmucosal route every 8 hours for 3 days) were administered. Famotidine, prednisolone, and diphenhydramine were continued at the previously determined doses. One month later, Belinda was again stable and maintaining a good quality of life.

#### Discussion

Cutaneous MCTs are the second most common skin neoplasm in cats. Although most feline cutaneous MCTs are benign, ≈10% are aggressive regardless of histologic type.<sup>1</sup> MCTs most frequently arise on the head and neck, followed by the trunk and limbs. There can be a solitary lesion, clusters of lesions, or widespread distribution of lesions ranging from papules and plaques to discrete nodules in the skin or subcutis. Cats may exhibit pruritus, erythema, or edema of the affected area.<sup>1</sup>

The mean age for development of MCTs is ≈10 years,<sup>1</sup> but periorbital MCTs are more common in younger cats.<sup>2</sup> There is no sex predisposition. Siamese cats may be more predisposed, especially when young, but MCTs in these patients often regress spontaneously within 24 months.<sup>3</sup>

MCTs generally exfoliate readily via fine-needle aspiration techniques. Mast cells are large round cells with a centralized purple nucleus often obscured by numerous dark purple granules that fill the abundant cytoplasm. The granules, especially in feline MCTs, can stain poorly with quick stains commonly used in many clinics, making in-clinic diagnosis challenging.<sup>1,4</sup>

Histologically, feline MCTs are divided into mastocytic (more common) and atypical (less common; previously classified as *histiocytic*) forms. The mastocytic form is further subdivided into well-differentiated and pleomorphic forms.<sup>1</sup> A well-differentiated MCT is typically composed of morphologically normal-appearing mast cells that have minimal anisocytosis and anisokaryosis.<sup>1</sup> Mitotic figures can be present but are uncommon. Small lymphocyte clusters can also be present.

Continues ▶

#### TREATMENT AT A GLANCE

- ▶ Pretreatment with diphenhydramine is recommended prior to MCT aspiration or surgery.<sup>9</sup>
- ▶ Surgical removal is the treatment of choice for a solitary cutaneous MCT. Tumor recurrence is low regardless of whether complete surgical excision is obtained.<sup>2,3</sup>
- ▶ Histopathology should be performed to determine MI, which is the most significant prognostic indicator for feline cutaneous MCTs.<sup>1</sup>
- ▶ Diphenhydramine, famotidine, and prednisolone can be used as medical therapy for feline cutaneous MCTs.<sup>9</sup>
- ▶ Consultation with a veterinary medical oncologist to discuss other chemotherapeutic options as necessary is recommended.<sup>8,9</sup>

## TAKE-HOME MESSAGES

- ▶ Cutaneous MCTs are the second most common skin neoplasm in cats<sup>1</sup> and are generally seen in older cats; however, periorbital MCTs are more common in younger cats.<sup>2</sup>
- ▶ Young Siamese cats may be more prone to developing cutaneous MCTs, which can spontaneously regress.<sup>3</sup>
- ▶ Feline cutaneous MCTs are usually benign, regardless of histologic type, and recurrence at the site is low regardless of complete surgical excision, although new tumors can occur. Uncommonly, cutaneous MCTs can be aggressive or associated with visceral (splenic or intestinal) disease.<sup>1-3</sup>
- ▶ Mast cells exfoliate well with aspiration; however, the granules may stain poorly with quick stains, especially in cats. Cytologic diagnosis should be confirmed by a clinical pathologist.<sup>1,4</sup>
- ▶ MI is the most important prognostic indicator in feline cutaneous MCTs; high MI (>5 per 10 HPFs) is associated with a poorer prognosis.<sup>1</sup>
- ▶ Clinical staging should ideally include CBC, serum chemistry profile, urinalysis, lymph node aspiration, abdominal ultrasonography with splenic aspiration, thoracic radiography, and possibly bone marrow aspiration.<sup>1</sup>
- ▶ Up to 10% of cats with a single cutaneous MCT can have circulating mast cells, making CBC with blood smear review the minimum necessary diagnostic recommendation prior to surgery.<sup>1</sup>

## The most important prognostic factor for feline cutaneous MCTs is mitotic index (MI).

HPF = high-power field  
MCT = mast cell tumor  
MI = mitotic index

Spindle cell infiltrates can be seen in MCT aspirates but are less common in feline tumors as compared with canine tumors.<sup>1</sup> Mast cells in pleomorphic tumors exhibit more variability (including anisocytosis and anisokaryosis) and eosinophilic infiltrates.<sup>1</sup> The cytology of atypical MCTs more closely resembles histiocytes, as opposed to mast cells, and can also contain lymphocytic and eosinophilic infiltrates.<sup>1</sup> The cytologic features seen in pleomorphic and atypical MCTs do not correlate with malignant behavior.<sup>1</sup>

The most important prognostic factor for feline cutaneous MCTs is mitotic index (MI). Low MI (ie, <1 per 10 high-power fields [HPFs]) is associated with a better prognosis. High MI (ie, >5 per 10 HPFs) is associated with a poorer prognosis. Other factors associated with poor prognosis include multiple (>5) simultaneous cutaneous tumors, spread to local lymph nodes, low or moderate cytoplasmic granularity, and a high Ki67 index.<sup>1</sup>

The treatment of choice for a solitary cutaneous MCT is surgical removal. Studies demonstrate that tumor recurrence is low regardless of whether complete surgical excision is obtained.<sup>2,3</sup> Multiple de novo cutaneous MCTs occur in a significant number of cats, and pet owners should be advised of this possibility.<sup>1</sup> Additional clinical staging should be considered for all cats with cutaneous MCTs, but cats with any factors for poor prognosis (eg, high mitotic tumor index, >5 simultaneous cutaneous tumors, others as mentioned previously) and cats with visceral MCTs should be fully staged with an evaluation that includes CBC, serum chemistry profile, urinalysis, lymph node aspiration, abdominal ultrasonography with splenic aspiration, thoracic radiography, and possibly bone marrow aspiration. Mastocytosis is more common in cats with MCTs as compared with dogs, and ≈10% of cats with a single cutaneous MCT have mastocytosis.<sup>1</sup>

Medical treatment for feline cutaneous MCTs may include diphenhydramine (2-4 mg/kg PO every 12 hours), famotidine (1 mg/kg PO every 12 hours), and prednisolone (1-2 mg/kg PO every 24 hours to start).<sup>5-7,8</sup> Other potential treatment options may include chemotherapy (eg, lomustine), small

molecule inhibitors (eg, imatinib mesylate [tyrosine kinase inhibitor]), and radiation therapy. These therapies may increase survival in some cats; consultation with a veterinary medical oncologist is therefore strongly recommended.<sup>8-10</sup>

## References

1. Meuten DJ. Feline mast cell tumors. In: Meuten DJ. *Tumors in Domestic Animals*. 5th ed. John Wiley & Sons; 2017:195-199, 956.
2. Newkirk KM, Rohrbach BW. A retrospective study of eyelid tumors from 43 cats. *Vet Pathol*. 2009;46(5):916-927.
3. Litster AL, Sorenmo KU. Characterization of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. *J Feline Med Surg*. 2006;8(3):177-183.
4. Raskin RE, Meyer DJ. Mast Cell Tumor. In: Raskin RE, Meyer DJ. *Canine and Feline Cytology: A Color Atlas and Interpretation Guide*. 3rd ed. Elsevier; 2016:80-82.
5. Plumb DC. Diphenhydramine. Plumb's Veterinary Drugs. Updated September 2020. Accessed October 1, 2021. <https://app.plumbs.com/drug-monograph/tDYQtMqVRGPROD>
6. Plumb DC. Famotidine. Plumb's Veterinary Drugs. Updated September 2020. Accessed October 1, 2021. <https://app.plumbs.com/drug-monograph/9h9AS93L6IPROD>
7. Plumb DC. Prednisolone. Plumb's Veterinary Drugs. Updated September 2020. Accessed October 1, 2021. <https://app.plumbs.com/drug-monograph/sShl11M9aPPROD>
8. London CA, Thamm DH. Mast cell tumors. In: Vail DM, Thamm DH, Liptak JM, eds. *Winthrow and MacEwen's Small Animal Clinical Oncology*. 6th ed. Elsevier; 2020:382-403.
9. Henry C, Herrera C. Mast cell tumors in cats: clinical update and possible new treatment avenues. *J Feline Med Surg*. 2013;15(1):41-47.
10. London CA. Tyrosine kinase inhibitors in veterinary medicine. *Top Companion Anim Med*. 2009;24(3):106-112.

***pill at will!***<sup>™</sup>



**Vetnique**<sup>®</sup>  
+labs

**gulpz**<sup>™</sup>

### Pill Hiding Probiotic Supplement

Gulpz<sup>™</sup> is uniquely formulated to support the health needs of pets while on medications. They include Probiotics, Ginger, & Omegas to support digestion, plus Pill Matrix<sup>™</sup> Technology to hold pills securely.



Order Your **FREE**  
**Clinic Sample** at  
**BRIEF.GULPZ.COM**



**References**

1. Lottati M, Aucoin D, Bruyette DS. Expected total thyroxine (TT4) concentrations and outlier values in 531,765 cats in the United States (2014-2015). *PLoS One*. 2019;14(3):e0213259.
2. Peterson ME. Feline focus: diagnostic testing for feline thyroid disease: hyperthyroidism. *Compend Contin Educ Vet*. 2013;35(8):E3.
3. Jordan A, Gray R, Terkildsen M, Krockenberger M. Biological variation of total thyroxine (T4), free T4 and thyroid-stimulating hormone in 11 clinically healthy cats. *J Feline Med Surg*. 2021;23(6):592-597.
4. Feldman EC, Nelson RW. Feline hyperthyroidism (thyrotoxicosis). In: Feldman EC, Nelson RW. *Canine and Feline Endocrinology and Reproduction*. 3rd ed. Saunders; 2004:156-178.
5. Wehner A, Koehler I, Ramspott S, Hartmann K. Relationship between total thyroxine, thyroid palpation and a clinical index in hyperthyroid and healthy cats and cats with other diseases. *J Feline Med Surg*. 2019;21(8):741-749.
6. Peterson ME, Guterl JN, Nichols R, Rishniw M. Evaluation of serum thyroid-stimulating hormone concentration as a diagnostic test for hyperthyroidism in cats. *J Vet Intern Med*. 2015;29(5):1327-1334.
7. Wakeling J, Elliott J, Syme H. Evaluation of predictors for the diagnosis of hyperthyroidism in cats. *J Vet Intern Med*. 2011;25(5):1057-1065.
8. Carney HC, Ward CR, Bailey SJ, et al. 2016 AAFP guidelines for the management of feline hyperthyroidism. *J Feline Med Surg*. 2016; 18(5):400-416.
9. Hui TY, Bruyette DS, Moore GE, Scott-Moncrieff JC. Effect of feeding an iodine-restricted diet in cats with spontaneous hyperthyroidism. *J Vet Intern Med*. 2015;29(4):1063-1068.



**EUTHABAG®**

Depart with dignity.

They are part of the family.  
There is no ritual when they leave.  
EUTHABAG can help to bring closure.  
SHOW THEM HOW MUCH YOU CARE.



**Average cost: \$8**

**A CUSTOMIZABLE PET BODY BAG THAT HONORS THE BOND**

Above photo illustrates an example of custom artwork and is not a standard feature of the actual product.



Request a free sample at  
[euthabag.com/freesamples](http://euthabag.com/freesamples)

7 RACE credits on our  
FREE CE platform

[veterinaryeuthanasiaeducation.com](http://veterinaryeuthanasiaeducation.com)

DISTRIBUTED BY



Available at all major veterinary local distributors.

# Splenomegaly in Dogs

Elijah Ernst, DVM

Karyn Harrell, DVM, DACVIM (SAIM)

North Carolina State University

Following are differential diagnoses for dogs presented with splenomegaly.\*

- ▶ Infiltrative disease
  - Neoplasia
    - Hemangiosarcoma (may be focal enlargement or mass as opposed to diffuse splenomegaly)
    - Lymphoma
    - Mast cell tumor
    - Plasma cell neoplasia
    - Histiocytic sarcoma (diffuse or focal enlargement)
    - Other sarcomas (eg, leiomyosarcoma, fibrosarcoma; often focal enlargement)
    - Leukemia
  - Amyloidosis
- ▶ Infectious disease
  - Bacterial
    - Brucellosis
    - Rickettsial (ie, ehrlichiosis, anaplasmosis)
    - Salmonellosis
    - Tularemia
  - Viral
    - Infectious canine hepatitis
  - Fungal
    - Histoplasmosis
  - Protozoal
    - Babesiosis
    - Hepatozoonosis
- ▶ Reactive/hyperplastic changes (often cause focal enlargement)
  - Lymphoid hyperplasia
  - Nodular hyperplasia
    - Splenic
    - Complex
  - Lymphoid
- ▶ Congestion
  - Anesthesia/sedation
  - Right-sided congestive heart failure
  - Portal hypertension
  - Splenic vein thrombosis
  - Splenic torsion
- Extramedullary hematopoiesis (eg, bone marrow failure [myelofibrosis, myelophthisis, toxicity, immune-mediated disease, radiation], tissue inflammation or injury, hypoxia, hemolytic anemia, splenic hematoma, splenic thrombosis, lymphoid hyperplasia)
- Hematoma

\*Splenomegaly refers to diffuse enlargement unless otherwise noted.

## Suggested Reading

- Corbin EE, Cavanaugh RP, Schwartz P, Zawadzki KI, Donovan T. Splenomegaly in small-breed dogs: 45 cases (2005-2011). *J Am Vet Med Assoc*. 2017;250(10):1148-1154.
- Džaja P, Grabarević Ž, Rakočević S, et al. Atypical disseminated canine histoplasmosis - a case report. *Vet Arhiv*. 2004;74(2):165-173.
- Hensel ME, Negron M, Arenas-Gamboa AM. Brucellosis in dogs and public health risk. *Emerg Infect Dis*. 2018;24(8):1401-1406.
- Johns, JL, Christopher, MM. Extramedullary hematopoiesis: a new look at the underlying stem cell niche, theories of development, and occurrence in animals. *Vet Pathol*. 2012;49(3):508-523.
- Johnson KA, Powers BE, Withrow SJ, Sheetz MJ, Curtis CR, Wrigley RH. Splenomegaly in dogs. Predictors of neoplasia and survival after splenectomy. *J Vet Intern Med*. 1989;3(3):160-166.
- Kim J. A case of acute splenic vein thrombosis in a dog. *J Vet Med Sci*. 2019;81(10):1492-1495.
- Sarma K, Mondal DB, Saravanan M. Ultrasonographic changes in dogs naturally infected with tick borne intracellular diseases. *J Parasit Dis*. 2016;40(2):248-251.
- Takahashi M, Tomiyasu H, Hotta E, et al. Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan. *J Vet Med Sci*. 2014;76(5):661-666.
- Valli VE, Bienzle D, Linder KE, DJ Meuten. Tumors of the hemolymphatic system. In: Meuten DJ, ed. *Tumors in Domestic Animals*, 5th ed. Wiley-Blackwell; 2020:318-320.

# Laverdia™ -CA1

(verdinexor tablets)

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526

## Antineoplastic Tablets

### For Dogs Only

**CAUTION:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. **It is a violation of the law to use this product other than as directed in the labeling.**

**BRIEF SUMMARY** (for full prescribing information, see package insert)

**DESCRIPTION:** Laverdia-CA1 (verdinexor tablets) is a selective inhibitor of nuclear export (SINE) that blocks chromosome region maintenance 1 (CRM1).

**INDICATION:** Laverdia-CA1 is indicated for the treatment of lymphoma in dogs.

**CONTRAINDICATIONS:**

Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia-CA1 is a possible teratogen and can affect female and male fertility.

**WARNINGS:** NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA-CA1. Children should not come in contact with the feces, urine, vomit, or saliva of treated dogs.

Pregnant women, women who may become pregnant, and nursing women should not handle or administer Laverdia-CA1 or come in contact with the feces, urine, vomit, or saliva from Laverdia-CA1-treated dogs.

Laverdia-CA1 may cause birth defects and can affect female fertility based on animal studies.

Wear protective disposable chemotherapy resistant gloves when handling Laverdia-CA1 to avoid exposure to drug.

Wear protective disposable chemotherapy resistant gloves to prevent direct contact with moistened, broken, or crushed Laverdia-CA1 tablets and prevent direct contact with feces, urine, vomit, and saliva during treatment and for **3 days** after the dog has received the last treatment. Place all waste material in a plastic bag and seal before general disposal. Wash hands immediately and thoroughly with soap and water if contact occurs with the feces, urine, vomit, or saliva from Laverdia-CA1 treated dogs.

Any items that come in contact with feces, urine, vomit, or saliva should not be washed with other laundry during treatment and for **3 days** after the last treatment with Laverdia-CA1.

Wear protective disposable chemotherapy resistant gloves when handling the dog's toys, food bowl, and water bowl. Wash food and water bowls separately from other items during treatment and for **3 days** after the dog has received the last treatment.

If Laverdia-CA1 is accidentally ingested, or if there is significant contact with feces, urine, vomit or saliva of dogs during treatment or within **3 days** after the last treatment without proper precautions, seek medical advice immediately. It is important to show the treating physician a copy of the package insert, label, or client information sheet.

*Special instructions for handling and administering the product*  
It is recommended that Laverdia-CA1 be administered under the supervision of, or in consultation with, a veterinarian experienced in the use of cancer therapeutic agents.

Do not store near food, in or near a food preparation area, or with medications intended for use in humans.

*Skin contact*

In case of contact with the skin, wash the affected area immediately and thoroughly with soap and water.

*Accidental eye exposure*

Rinse the eyes with large amounts of tap water (use eyewash station if present) for 10 minutes while holding back the eyelid.

Remove contact lenses.

Seek medical advice immediately and show the package insert or label to the physician.

*Accidental oral exposure or ingestion*

Seek medical advice immediately and show the package insert or label to the physician.

### Animal Safety Warnings

Laverdia-CA1 can cause severe anorexia. Patients should be carefully monitored for inappetence, vomiting, diarrhea and dehydration, and supportive care should be provided as clinically indicated. Keep Laverdia-CA1 in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

**PRECAUTIONS:** Safe use of Laverdia-CA1 has not been evaluated in dogs with concurrent serious infections; concurrent renal, cardiovascular, or hepatic disease; in dogs with diabetes mellitus; in dogs with clinically relevant hypercalcemia; in dogs with concurrent malignancy or dogs younger than 7 months of age.

Laverdia-CA1 can cause hematologic and serum chemistry abnormalities. Dogs should be frequently monitored for evidence of hematologic and serum chemistry abnormalities when initiating and maintaining treatment with Laverdia-CA1 (see ADVERSE REACTIONS).

The safety and effectiveness of Laverdia-CA1 has not been evaluated in conjunction with other chemotherapeutic agents or other treatment modalities for lymphoma.

**ADVERSE REACTIONS:** The most common adverse events reported during the course of a US field study supporting reasonable expectation of effectiveness were lethargy, fever, weakness, generalized pain, anorexia, vomiting, diarrhea, polyuria, polydipsia, hematuria, proteinuria, elevated liver enzymes, bilirubinuria, cough/dyspnea, weight loss, blood cell abnormalities, subcutaneous edema, and pyoderma. Less common adverse reactions seen were protein losing nephropathy, urinary incontinence, hepatomegaly, elevated bilirubin, icterus, heart murmur, arrhythmia, heart block, blood protein abnormalities, prolonged prothrombin time, seizure, tremor, disorientation, corneal opacity, skin bruising, redness, loss of hair, nasal discharge, epistaxis, lymphadenitis and platelet abnormalities.

To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Dechra Veterinary Products at 1-833-264-8483. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/reportanimalae>.

**DISTRIBUTED BY:**

Dechra Veterinary Products  
7015 College Boulevard, Suite 525  
Overland Park, KS 66211 USA

Conditionally Approved by FDA under application number 141-526

Laverdia™ is a trademark of Dechra Limited.


R 02 2022

14BR-LAV22005-0222



# LAVERDIA™-CA1 verdinexor

## The Power to Treat Lymphoma In a pill



### A novel treatment option for canine lymphoma patients

LAVERDIA™-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.

#### Important Safety Information

For use in dogs only. LAVERDIA™-CA1 (verdinexor) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA™-CA1. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer LAVERDIA-CA1 or come into contact with the feces, urine, saliva, or vomit of treated dogs for 3 days following treatment. Laverdia-CA1 can affect male fertility based on animal studies and studies in humans. Wear protective disposable chemotherapy resistant gloves when handling Laverdia-CA1 to avoid direct exposure to moistened, broken or crushed tablets or biological waste from the treated dog (feces, urine, saliva, or vomit). Do not use in dogs that are pregnant, lactating or intended for breeding. LAVERDIA-CA1 is a possible teratogen and can affect female and male fertility. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. The most commonly reported adverse reactions in dogs include anorexia, weight

loss, vomiting, diarrhea, and lethargy polyuria, polydipsia, elevated liver enzymes and thrombocytopenia. Please see package insert or visit [dechra-us.com](http://dechra-us.com) for full prescribing information.

For product label, including complete safety information, visit [go.dechra-us.com/laverdia-pi](http://go.dechra-us.com/laverdia-pi), or scan the QR code below.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as Directed. It is a violation of Federal Law to use this product other than as directed in the labeling.

Laverdia™ is a trademark of Dechra Ltd.  
©2022 Dechra Veterinary Products. All rights reserved. 14SD-LAV22015-0322



clinician's brief<sup>®</sup>

CAREER CENTER



**BUILDING AN A-TEAM IS NEVER EASY**

**BUT IT'S *EASIER* WITH A PARTNER WHO  
KNOWS WHAT YOU'RE LOOKING FOR**

The *Clinician's Brief* Career Center helps you cut through the noise to reach the best hires in veterinary medicine.

Start connecting with the most qualified job seekers at  
[cliniciansbrief.com/career-center](https://www.cliniciansbrief.com/career-center)

# Digit Amputation in Dogs

**Ka Yung Lee, DVM**  
Tuskegee University

**Judith Bertran, DVM, MS, DACVS (SA)**  
University of Florida



Digit amputation is indicated in dogs with digital or subungual neoplasms, degloving/shearing wounds of the foot, chronic sprains or luxations, phalangeal or intra-articular fractures, chronic osteomyelitis, severe osteoarthritis, or chronic severe dermal diseases (eg, chronic severe acral lick dermatitis), as well as in dogs requiring distal foot skin reconstruction via phalangeal fillet techniques.<sup>1</sup>

Amputation is generally performed at the metacarpophalangeal or metatarsophalangeal joints, especially in patients with neoplasms or osteomyelitis. More distal amputations are reserved for patients with traumatic or degenerative diseases that only affect the distal phalanges. Amputation of the second or fifth digit does not affect limb function; however, amputation of the third

or fourth digits, which are weight-bearing, may affect function or result in mechanical lameness.<sup>2</sup>

The surgical principles of proximal and distal interphalangeal joint amputation and metacarpophalangeal and metatarsophalangeal joint amputation are similar.<sup>1,2</sup> The digital pad is preserved in proximal and distal interphalangeal joint amputation but is removed in metacarpophalangeal and metatarsophalangeal joint amputation, most frequently performed for digit amputation.<sup>1,2</sup> If the location is distal (second or third phalanx) and the condition is benign, amputation at the interphalangeal joints can be performed.

Malignant lesions usually require soft tissue and bone margins (wide surgical excision) for cancer-free excision at the surgical margin. Distal malignant lesions are thus usually excised at the metacarpophalangeal or metatarsophalangeal joints. Ring block or regional analgesia can be performed using longer-lasting anesthetics (eg, bupivacaine, liposome-encapsulated bupivacaine).

## STEP-BY-STEP DIGIT AMPUTATION

### WHAT YOU WILL NEED

- ▶ #15 scalpel blade
- ▶ Rongeur
- ▶ Electrocautery tool (recommended)
- ▶ Metzenbaum scissors
- ▶ Monofilament nonabsorbable suture (4-0 or 3-0)
- ▶ Monofilament absorbable suture (4-0 or 3-0)
- ▶ Needle holder
- ▶ Bandage materials
- ▶ Esmarch tourniquet
  - Adherent wrap
  - Scissors

## METACARPOPHALANGEAL & METATARSOPHALANGEAL JOINT AMPUTATION

### STEP 1

To exsanguinate the limb, tightly apply an Esmarch bandage from the most distal aspect of the toes to 2 to 3 cm proximal to the carpus or the tarsus. Tightly secure the bandage at the proximal aspect of the limb to prevent blood from flowing into the limb during surgery. Cut the bandage from distal to proximal to expose the surgical site (up to the carpus or tarsus), leaving the most proximal aspect of the tourniquet intact. Be careful not to cut the skin.

### Author Insight

Applying an Esmarch bandage prevents the limb from bleeding and removes blood from the limb. There are many advantages of a bloodless surgery, but it may be difficult to identify when large vessels are punctured, and ligation may be required. In addition, use of an Esmarch bandage can result in regional ischemia; the surgeon should work quickly and be conscious of surgical time to minimize ischemic morbidity of the distal aspect of the extremity. A tourniquet should not be used longer than 1 to 2 hours and should be removed as soon as possible.<sup>3</sup>

### STEP 2

Beginning on the dorsal aspect of the affected digit, make an inverted Y-shaped skin incision along the sides of the digit that meets on the palmar aspect.<sup>4</sup>

### Author Insight

This incision results in a straight line after suturing and allows removal of the digital pad. If the digit is removed because of a neoplastic condition, the incision shape may require modification to incorporate the skin margin necessary for wide surgical excision.



### STEP 3

Ligate or cauterize arteries and veins that are <1 to 2 mm in diameter and located axially or abaxially at the dorsal (dorsal common digital vasculature) and ventral (palmar common digital vasculature) aspects of the digit.<sup>5</sup>

### STEP 4

Transect the tendons of the superficial and deep digital flexor (palmar), as well as the common digital extensor (dorsal, thoracic limb) or long digital extension (dorsal, pelvic limb) at the level of the proximal phalanx and the metacarpal (or metatarsal) bone.<sup>5</sup>



### STEP 5

Carefully transect the joint capsule at the level of the phalanx and the corresponding metacarpal (or metatarsal) bone to be amputated. Avoid direct mechanical damage to the cartilage,<sup>5</sup> and remove the digit. Perform a condylectomy if needed to allow cosmetic closure of the skin.

### Author Insight

There is controversy in human and veterinary medicine on whether condylectomy increases pain. Condylectomy causes a disturbance of the joint cartilage and subchondral bone, which remains exposed to deeper tissue, potentially increasing pain.<sup>6</sup> The third and fourth metacarpal and metatarsal bones may require condylectomy, and the second and fifth metacarpal bones may be beveled on the medial and lateral aspect, respectively.



Continues ►

## STEP 6

Remove the tourniquet.

### Author Insight

Hemostasis with cautery or ligations is often necessary before closure. The tourniquet can be removed at the end of the procedure, immediately before adding a soft, padded bandage. The authors remove the tourniquet prior to tissue closure to visualize excessive bleeding and ensure hemostasis prior to suturing. Removing the tourniquet prior to closure also minimizes how long the tourniquet is applying active pressure, decreasing tourniquet-associated morbidity.



## STEP 7

Suture subcutaneous tissue with a simple interrupted pattern using a 3-0 or 4-0 monofilament absorbable suture (A). Suture the skin with a cruciate pattern using a 3-0 or 4-0 monofilament non-absorbable suture (B).



## STEP 8

Provide postoperative multimodal pain management with injectable analgesics (ie, mu agonist opioids) for the first 12 to 24 hours and oral analgesics (eg, NSAIDs, gabapentin, tramadol) after the patient recovers and has normal deglutition.

## STEP 9

Use a soft, padded bandage for 1 to 2 weeks (if tolerated by the patient) to prevent trauma to the incision while walking. Restrict exercise for 3 weeks until the wound heals.

# PROXIMAL & DISTAL INTERPHALANGEAL JOINT AMPUTATION

## STEP 1

To exsanguinate the regional distal area of the limb, tightly apply an Esmarch bandage from the most distal aspect of the toes to 2 to 3 cm proximal to the carpus or the tarsus. Tightly secure the bandage at the proximal aspect of the limb to prevent blood from flowing into the limb during surgery. Cut the bandage from distal to proximal to expose the surgical site (up to the carpus or tarsus), leaving the most proximal aspect of the tourniquet intact. Be careful not to cut the skin.

### Author Insight

Applying an Esmarch bandage prevents the limb from bleeding and removes blood from the limb. There are many advantages of a bloodless surgery, but it may be difficult to identify when large vessels are punctured, and ligation may be required. In addition, use of an Esmarch bandage can result in regional ischemia; the surgeon should work quickly and be conscious of surgical time to minimize ischemic morbidity of the distal aspect of the extremity. A tourniquet should not be used longer than 1 to 2 hours and should be removed as soon as possible.<sup>3</sup>

## STEP 2

Make a skin incision that encircles the nail (around the ungual process), sparing the digital pad. Continue the incision proximally and dorsally (over the phalangeal bone) to expose the distal interphalangeal joint or the proximal interphalangeal joint depending on the determined level of amputation.

## STEP 3

Sharply dissect soft tissue away from the bone and transect the extensor tendons (dorsal), flexor tendons (palmar), and collateral ligaments (lateral).

## STEP 4

Disarticulate the joint.

### Author Insight

There is controversy in human and veterinary medicine on whether condylectomy increases pain. Condylectomy causes a disturbance of the joint cartilage and subchondral bone, which remains exposed to deeper tissue, potentially increasing pain.<sup>6</sup> The third and fourth metacarpal and metatarsal bones may require condylectomy, and the second and fifth metacarpal bones may be beveled on the medial and lateral aspect, respectively.

Continues ►

## STEP 5

Suture the subcutaneous tissue with an appositional, interrupted knot-burying pattern to maximize wound healing and prevent wound dehiscence in a high-motion area. Create a Y-shaped pattern by pulling the digital pad over the cut end of the bone and suturing (both sides) laterally and dorsally.

## STEP 6

Suture the skin with a simple interrupted pattern using a 3-0 or 4-0 monofilament nonabsorbable suture, which can typically be removed 2 to 3 weeks postoperatively.

## STEP 7

Provide postoperative multimodal pain management with injectable analgesics (ie, mu agonist opioids) for the first 12 to 24 hours and oral analgesics (eg, NSAIDs, gabapentin, tramadol) after the patient recovers and has normal deglutition.

## STEP 8

Use a soft, padded bandage for 1 to 2 weeks (if tolerated by the patient) to prevent trauma to the incision when the patient walks. Restrict exercise for 3 weeks until the wound heals.

### Author Insight

The authors recommend applying a compressive bandage for the first week (if tolerated and no bandage morbidity occurs). Although motion at the surgical site is unavoidable, some surgeons prefer to apply a stiffer bandage by adding a palmar/plantar-located splint for one week to help minimize movement of the digits. Use of a splint should be weighed against the risk for morbidity due to increasing pressure points on a wound area. ■

## References

1. DeCamp CE, Johnston SA, Déjardin LM, Schaefer SL. Amputation of toe. In: DeCamp CE, ed. *Brinker, Piermattei, and Flo's Handbook of Small Animal Orthopedics and Fracture Repair*. 5th ed. Elsevier; 2016:430-432.
2. Kapatkin AS, Garcia-Nolen T, Hayashi K. Digit amputation. In: Tobias KM, Johnston SA, eds. *Veterinary Surgery Small Animal*. Elsevier Saunders; 2012:799-800.
3. Rorabeck CH. Tourniquet-induced nerve ischemia: an experimental investigation. *J Trauma*. 1980;20(4):280-286.
4. Probst CW, Millis DL. Digit amputation. In: Slatter D, ed. *Textbook of Small Animal Surgery*. 3rd ed. Saunders; 2003:1974-1988.
5. Evans HE, de Lahunta A. The skeletal and muscular systems. In: *Miller's Anatomy of the Dog*. 4th ed. Elsevier Saunders; 2013:7-92.
6. Li A, Meunier M, Rennekampff HO, Tenenhaus M. Surgical amputation of the digit: an investigation into the technical variations among hand surgeons. *Eplasty*. 2013;13:e12.

# ADVERTISERS INDEX

The *Clinician's Brief* Advertisers Index is provided as a service to our readers. The publisher does not assume responsibility for any errors or omissions.

- American Heartworm Society** | heartwormsociety.org | page 48 | American Heartworm Society
- Antech Diagnostics** | q-r.to/antech-briefc-0422 | cover insert | Antech Diagnostics
- Clinician's Brief Algorithm Collection** | cliniciansbrief.com/algorithms | page 50 | Brief Media
- Clinician's Brief Career Center** | cliniciansbrief.com/career-center | page 64 | Brief Media
- Core Imaging Ultrasound Systems** | coreimaging.com | page 44 | Core Imaging
- CVM Veterinary Conference** | CVMCEC.org | page 37 | Nutramax Laboratories
- Dechra Rewards** | DechraRewards.com; vetcove.com/signup | page 22 | Dechra
- Dermaquin** | dermaquin.com | inside front cover | Nutramax Laboratories
- Epicur Pharma** | EpicurPharma.com | page 39 | Epicur Pharma
- Euthabag** | euthabag.com/freesamples; veterinaryeuthanasiaeducation.com | page 60 | Jorgensen Laboratories
- Gulpz** | brief.gulpz.com | page 59 | Vetnique Labs
- HeartGard Plus** | HeartGardClinic.com | back cover; page 71 | Boehringer Ingelheim
- Hill's Digestive Care and Urinary Care** | PrescriptionDiet.com/ BetterThanEver | page 8 | Hill's Pet Nutrition
- Laverdia-CA1** | go.dechra-us.com/laverdia-pi | pages 63, 62 | Dechra
- Nobivac Canine 1-DAPPv+L4** | nobivac.com | page 10 | Merck Animal Health
- Nocita** | elanco.com | pages 4-5 | Elanco
- Nutrition Exchange** | PurinaVeterinaryDiets.com | insert | Nestlé Purina Company
- OrthoLine Fracture Management System** | ArthrexVetSystems.com | page 2 | Arthrex Vet Systems
- Osurnia** | dechra-us.com | pages 33, 32 | Dechra
- Phovia** | vetoquinolusa.com/phovia | page 43 | Vetoquinol
- Plumb's Pro** | plumbs.com | page 47 | Brief Media
- Porus One** | dechra-us.com | inside back cover | Dechra
- Reconcile** | reconcile.com | pages 30, 29 | PRN Pharmacal
- Rescue** | RescueDisinfectants.com | page 40 | Virox
- Royal Canin** | my.royalcanin.com | page 17 | Royal Canin
- Veterinary HPM Spay and Neuter Diets** | vet-us.virbac.com/hpm | page 35 | Virbac
- Vetigel** | store.vetigel.com | page 54 | Cresilon
- Vetscan Imagyst** | vetscanimagyst.com | page 7 | Zoetis

## Photo Credits

© Shutterstock.com pages 13, 27, 41, 45, 51, 54

**Heartgard<sup>®</sup> Plus**  
(ivermectin/pyrantel)

### CHEWABLES

**CAUTION:** Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. **INDICATIONS:** For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (*Dirofilaria immitis*) for a month (30 days) after infection and for the treatment and control of ascarids (*Toxocara canis*, *Toxascaris leonina*) and hookworms (*Ancylostoma caninum*, *Uncinaria stenocephala*, *Ancylostoma braziliense*).

**DOSAGE:** HEARTGARD<sup>®</sup> Plus (ivermectin/pyrantel) should be administered orally at monthly intervals at the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb) and 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb) of body weight. The recommended dosing schedule for prevention of canine heartworm disease and for the treatment and control of ascarids and hookworms is as follows:

Dog Weight	CheWables Per Month	Ivermectin Content	Pyrantel Content	Color Coding On Foil Backing and Carton
Up to 25 lb	1	68 mcg	57 mg	Blue
26 to 50 lb	1	136 mcg	114 mg	Green
51 to 100 lb	1	272 mcg	227 mg	Brown

HEARTGARD Plus is recommended for dogs 6 weeks of age and older. For dogs over 100 lb use the appropriate combination of these chewables.

**ADMINISTRATION:** Remove only one chewable at a time from the foil-backed blister card. Return the card with the remaining chewables to its box to protect the product from light. Because most dogs find HEARTGARD Plus palatable, the product can be offered to the dog by hand. Alternatively, it may be added intact to a small amount of dog food. The chewable should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole.

Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

HEARTGARD Plus should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog's first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog's last exposure to mosquitoes.

When replacing another heartworm preventive product in a heartworm disease preventive program, the first dose of HEARTGARD Plus must be given within a month (30 days) of the last dose of the former medication.

If the interval between doses exceeds a month (30 days), the efficacy of ivermectin can be reduced. Therefore, for optimal performance, the chewable must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with HEARTGARD Plus and resumption of the recommended dosing regimen will minimize the opportunity for the development of adult heartworms.

Monthly treatment with HEARTGARD Plus also provides effective treatment and control of ascarids (*T. canis*, *T. leonina*) and hookworms (*A. caninum*, *U. stenocephala*, *A. braziliense*). Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.

**EFFICACY:** HEARTGARD Plus Chewables, given orally using the recommended dose and regimen, are effective against the tissue larval stage of *D. immitis* for a month (30 days) after infection and, as a result, prevent the development of the adult stage. HEARTGARD Plus Chewables are also effective against canine ascarids (*T. canis*, *T. leonina*) and hookworms (*A. caninum*, *U. stenocephala*, *A. braziliense*).

**ACCEPTABILITY:** In acceptability and field trials, HEARTGARD Plus was shown to be an acceptable oral dosage form that was consumed at first offering by the majority of dogs.

**PRECAUTIONS:** All dogs should be tested for existing heartworm infection before starting treatment with HEARTGARD Plus which is not effective against adult *D. immitis*. Infected dogs must be treated to remove adult heartworms and microfilariae before initiating a program with HEARTGARD Plus.

While some microfilariae may be killed by the ivermectin in HEARTGARD Plus at the recommended dose level, HEARTGARD Plus is not effective for microfilariae clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.

#### Keep this and all drugs out of the reach of children.

In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans. Store between 68°F - 77°F (20°C - 25°C). Excursions between 59°F - 86°F (15°C - 30°C) are permitted. Protect product from light.

**ADVERSE REACTIONS:** In clinical field trials with HEARTGARD Plus, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported following the use of HEARTGARD: Depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation.

To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

**SAFETY:** HEARTGARD Plus has been shown to be bioequivalent to HEARTGARD, with respect to the bioavailability of ivermectin. The dose regimens of HEARTGARD Plus and HEARTGARD are the same with regard to ivermectin (6 mcg/kg). Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target use level) than dogs of other breeds. At elevated doses, sensitive dogs showed adverse reactions which included mydriasis, depression, ataxia, tremors, drooling, paresis, recumbency, excitability, stupor, coma and death. HEARTGARD demonstrated no signs of toxicity at 10 times the recommended dose (60 mcg/kg) in sensitive Collies. Results of these trials and bioequivalency studies, support the safety of HEARTGARD products in dogs, including Collies, when used as recommended.

HEARTGARD Plus has shown a wide margin of safety at the recommended dose level in dogs, including pregnant or breeding bitches, stud dogs and puppies aged 6 or more weeks. In clinical trials, many commonly used flea collars, dips, shampoos, anthelmintics, antibiotics, vaccines and steroid preparations have been administered with HEARTGARD Plus in a heartworm disease prevention program.

In one trial, where some pups had parvovirus, there was a marginal reduction in efficacy against intestinal nematodes, possibly due to a change in intestinal transit time.

**HOW SUPPLIED:** HEARTGARD Plus is available in three dosage strengths (see DOSAGE section) for dogs of different weights. Each strength comes in convenient cartons of 6 and 12 chewables.

Marketed by  
Boehringer Ingelheim Animal Health USA Inc.  
Duluth, GA 30096


Made in U.S.A.

©HEARTGARD and the Dog & Hand Logo are registered trademarks of Boehringer Ingelheim Animal Health USA Inc.  
©2019 Boehringer Ingelheim Animal Health USA Inc.  
All Rights Reserved.

Rev. 08-2018

1050-1999-04.

US-PET-0199-2020.



## QUIZ YOURSELF

on this issue's  
features

Quiz Corner is offered by the publisher for entertainment purposes only and does not apply toward CE credit. Questions are provided by editorial staff and are not subject to peer review.

### 1 **DIAGNOSTIC/MANAGEMENT TREE PAGE 18**

- Which of the following findings would *not* be expected in a cat with nonthyroidal illness?
- A. Total thyroxine >3.5 µg/dL but within reference interval or within upper one-third of reference interval
  - B. Unexplained weight loss
  - C. Elevated ALT
  - D. Canine thyroid stimulating hormone <0.03 ng/mL

### 2 **DIAGNOSTIC/MANAGEMENT TREE PAGE 20**

- What is the next diagnostic step for a dog with decreased total thyroxine (tT<sub>4</sub>) on routine screening that is not on any medications that may affect tT<sub>4</sub> and does not show clinical signs of hypothyroidism?
- A. Euthyroid sick syndrome should be considered.
  - B. Thyroid stimulating hormone levels should be measured.
  - C. Free T<sub>4</sub> levels should be measured via equilibrium dialysis.
  - D. Trial of levothyroxine should be administered.

### 3 **TOP 5 PAGE 51**

- Which of the following statements regarding a stress leukogram is *false*?
- A. Neutrophilia is caused by decreased adherence to the vascular endothelium.
  - B. Prolonged circulation time may cause neutrophils to appear hyposegmented.
  - C. The segmented neutrophil count can double in dogs and triple in cats.
  - D. A left shift to band neutrophils and toxic changes are not expected due to lack of inflammatory response.

### 4 **CASE IN POINT PAGE 55**

- Which of the following statements regarding feline cutaneous mast cell tumor (MCT) is *false*?
- A. Most feline cutaneous MCTs are benign.
  - B. Feline MCT exfoliates poorly when a fine-needle aspiration technique is used.
  - C. Mitotic index is the most important prognostic factor for feline cutaneous MCT.
  - D. Feline cutaneous MCT recurrence is low after surgical removal, even if complete surgical excision is not obtained.

### 5 **PROCEDURES PRO PAGE 65**

- Amputation of the \_\_\_\_\_ digit may affect weight-bearing function.
- A. First
  - B. Second
  - C. Third

Answer Key:  
1: D 2: A 3: B 4: B 5: C



Available  
from Dechra!

**PORUS<sup>®</sup> ONE**

## For the support of feline kidney health

Porus<sup>®</sup> One is a selective carbon-based adsorber of protein byproducts with a large adsorption capacity.\* Porus One binds protein byproducts in the intestines where they are excreted in the feces.\* This binding process helps to prevent the byproducts from being converted into uremic toxins, which supports kidney health.

### Porus One is:

- Tasteless
- Odorless
- Administered at mealtime
- Readily accepted by cats\*\*

\*Data on file.

\*\*Mottet J, Kowollik N: BSAVA Congress Proceedings. 2019. 424-425.



For Veterinary Technical Support, Contact Dechra Veterinary Products at:  
(866) 933-2472 | [www.dechra-us.com](http://www.dechra-us.com) | [support@dechra.com](mailto:support@dechra.com)

Porus is a registered trademark of Porus GmbH. Dechra is a registered trademark of Dechra Pharmaceuticals PLC.  
© 2021 Dechra Veterinary Products. All rights reserved. 11AD-POR21031-1021



**Dechra**  
Veterinary Products

YOU SEE THIS  
**INVISIBLE  
THREAT.**  
YOUR CLIENTS DON'T.

HEARTGARD® Plus (ivermectin/pyrantel) has tools available to help you educate your clients about the real risks of heartworm disease. With HEARTGARD Plus, you're recommending:

- ✓ Safe and trusted heartworm disease prevention that's still #1 after 33 years<sup>1</sup>
- ✓ The #1 dog-preferred, real-beef chew that makes compliance enjoyable for pets and pet owners<sup>2</sup>
- ✓ Highly effective control of five species of common intestinal parasites<sup>3,4</sup>
- ✓ Prevention backed by the HEARTGARD Plus Satisfaction Guarantee



Get clinic support at **HEARTGARDClinic.com**

**IMPORTANT SAFETY INFORMATION:** HEARTGARD® Plus (ivermectin/pyrantel) is well tolerated. All dogs should be tested for heartworm infection before starting a preventive program. Following the use of HEARTGARD Plus, digestive and neurological side effects have rarely been reported. For more information, please see full prescribing information or visit [www.HEARTGARDClinic.com](http://www.HEARTGARDClinic.com).

<sup>1</sup> Data on file at Boehringer Ingelheim. <sup>2</sup> Data on file at Boehringer Ingelheim. <sup>3</sup> Ascarid for Dog, Companion Animal Parasite Council. <https://capcvet.org/guidelines/ascaris/>. Accessed December 2, 2020. <sup>4</sup> Hookworms for Dog, Companion Animal Parasite Council. <https://capcvet.org/guidelines/hookworms/>. Accessed December 2, 2020.